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Tetrahydropyrazino-annelated theophylline (1,3-dimethylxanthine) derivatives have
previously been shown to display increased water-solubility as compared to the
parent xanthines due to their basic character. In the present study, we modified
this promising scaffold by replacing the 1,3-dimethyl residues by a variety of
alkyl groups including combinations of different substituents in both positions.
Substituted benzyl or phenethyl residues were attached to the N8 of the resulting
1,3-dialkyl-tetrahydropyrazino[2,1-f ]purinediones with the aim to obtain multi-target
drugs that block human A1 and A2A adenosine receptors (ARs) and monoaminoxidase
B (MAO-B). 1,3-Diethyl-substituted derivatives showed high affinity for A1 ARs, e.g.,
15d (PSB-18339, 8-m-bromobenzyl-substituted) displayed a Ki value of 13.6 nM
combined with high selectivity. 1-Ethyl-3-propargyl-substituted derivatives exhibited
increased A2A AR affinity. The 8-phenethyl derivative 20h was selective for the A2A AR
(Ki 149 nM), while the corresponding 8-benzyl-substituted compound 20e (PSB-1869)
blocked A1 and A2A ARs with equal potency (Ki A1, 180 nM; A2A, 282 nM). The
1-ethyl-3-methyl-substituted derivative 16a (PSB-18405) bearing a m,p-dichlorobenzyl
residue at N8 blocked all three targets, A1 ARs (Ki 396 nM), A2A ARs (Ki 1,620 nM),
and MAO-B (IC50 106 nM) with high selectivity vs. the other subtypes (A2B and
A3 ARs, MAO-A), and can thus be considered as a multi-target drug. Our findings
were rationalized by molecular docking studies based on previously published X-ray
structures of the protein targets. The new drugs have potential for the treatment of
neurodegenerative diseases, in particular Parkinson’s disease.
Keywords: caffeine derivatives, anellated xanthines, tetrahydropyrazino[2, 1-f]purinediones, adenosine A2A
receptor antagonists, adenosine A1 receptor antagonists, monoamine oxidase (MAO) B inhibitors, Alzheimer’s
disease, Parkinson’s disease
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FIGURE 1 | Structures and Ki/IC50 values of the first marketed A2A-selective
AR antagonist istradefylline (1) and the non-selective AR antagonist caffeine (2)
(h = human; data taken from Petzer et al., 2009; Müller and Jacobson, 2011;
Brunschweiger et al., 2014).
INTRODUCTION
Adenosine receptors (ARs), specifically those of the A2A
subtype, have emerged as new targets for neurodegenerative
diseases, in particular for Parkinson’s (PD) and Alzheimer’s
disease (AD). Several A2A-selective AR antagonists have been
evaluated in preclinical and clinical trials. The 8-stryrylxanthine
derivative istradefylline (Nouriast R©, 1, Figure 1) was approved
in Japan as adjunctive treatment of PD in combination with
levodopa (Dungo and Deeks, 2013). The consumption of
caffeine (2), which is a weakly potent and non-selective AR
antagonist (Figure 1), was found to protect from PD and AD
as demonstrated in a number of animal models as well as in
large epidemiological studies in humans (Chen and Chern, 2011;
Flaten et al., 2014).
The concept of multi-target drugs interacting simultaneously
with two or more pharmacological targets was proposed as
a strategy for the treatment of complex diseases such as
cancer, psychiatric disorders and neurodegenerative diseases
(Geldenhuys and Van Der Schyf, 2013). Multi-target drugs may
exhibit high efficacy due to synergistic effects, show a reduced risk
of side effects, and result in improved compliance, especially in
elderly patients, as compared to combination therapies of two or
more different drugs.
In 2009, Petzer et al. suggested that simultaneous targeting
of the dopamine-metabolizing, H2O2-producing enzyme
monoamine oxidase B (MAO-B) by inhibitors, and of A2A ARs
by antagonists, may be advantageous for the treatment of PD due
to their dopamine-enhancing effects. While MAO-B inhibition
directly inhibits the degradation of dopamine, A2A AR blockade
enhances dopamine-induced D2 receptor signaling in the
A2A-D2 heteromeric receptor (Navarro et al., 2018). In addition,
A2A AR antagonists reduce cAMP production by blocking A2A
AR-induced activation of adenylate cyclase (AC); thus they
exert the same intracellular effect as dopamine receptor agonists
activating Gi protein-coupled receptors, thereby also inhibiting
AC. Moreover, both, MAO-B inhibition and A2A AR blockade,
are expected to show additional neuroprotective activities,
MAO-B inhibitors by reducing hydrogen peroxide production,
and A2A AR antagonists by various mechanisms (Fišar, 2016;
Xu et al., 2016). Therefore, such a dual target-directed approach
may result in synergistic or at least additive effects thereby
possibly halting or reducing the devastating progression of
neurodegenerative diseases.
Several studies focused on the design of caffeine derivatives
that display A2A AR antagonistic as well as MAO-B inhibitory
activity have been published (Petzer and Petzer, 2015). 8-m-
Chlorostyrylcaffeine (CSC, 3) was the first reported example
of an A2A AR antagonist that also showed high MAO-B
inhibitory activity (Figure 2; Chen et al., 2002). Petzer and
coworkers reported on a series of (E,E)-8-(4-phenylbutadien-1-
yl)xanthines, among which caffeine derivative 4 showed potent
A2A AR/MAO-B inhibitory activity (Ki rat A2A AR: 59.1 nM;
IC50 human MAO-B: 37.9 nM) (Pretorius et al., 2008). Recently,
Wang et al. published another series of xanthine-based dual A2A
AR antagonists/MAO-B inhibitors. The most potent example of
this series was PX-D-P6 (5) (Ki human A2A AR: 330 nM; IC50
human MAO-B: 260 nM), which showed anti-cataleptic effects
in a haloperidol model in rat (Wang et al., 2017). The first non-
xanthine-derived dual A2A AR antagonists/MAO-B inhibitors
were reported by our group: N-(4-oxo-4H-3,1-benzothiazin-
2-yl)-4-phenylbutanamide (6, Figure 2) was the most potent
compound in that series of benzothiazines displaying a Ki value
of 39.5 nM at the human A2A AR, and an IC50 value of 34.9 nM at
human MAO-B combined with excellent selectivity vs. other AR
subtypes as well as vs. MAO-A (Stössel et al., 2013).
As a further dual-target drug approach for the treatment
of PD, the combination of A2A and A1 AR blockade was
suggested. The dual A1/A2A AR antagonist ASP-5854 (7) (Ki
human A1 9.03 nM; Ki human A2A 1.76 nM) was extensively
characterized in several animal models of PD, as well as for its
effects on cognition. Compound 7 reversed haloperidol-induced
catalepsy in monkeys. Moreover, it produced positive results
in rats in the passive avoidance test, a model of cognition, in
which the A2A-selective antagonist istradefylline (1) had been
inactive (Mihara et al., 2007). The aminopyrimidine-based dual
A1/A2A AR antagonist 8, which displays high affinity for both
AR subtypes (Ki rat A1 6.34 nM; Ki rat A2A 9.54 nM), showed
in vivo efficacy in a rat model of haloperidol-induced catalepsy
(Robinson et al., 2015). These results support the hypothesis that
a dual A1/A2A AR antagonist may provide additional benefit to
PD patients as compared to antagonists that selectively block A2A
ARs, due to their positive effects on cognitive impairment often
associated with the disease.
We previously reported on the development of
tetrahydropyrimido[2,1-f ]purinediones (e.g., compounds
9a, 9b) as AR antagonists and MAO-B inhibitors (Figure 3;
Drabczynska et al., 2007; Koch et al., 2013). This class of
compounds can be envisaged as tricyclic caffeine derivatives.
They represent analogs of 8-styrylxanthines, that are sterically
constrained by anellation of a tetrahydropyrimidine ring to
the 7,8-position of xanthine mimicking the (E)-configurated
styryl sub-structure of CSC (6). Compound 9a is a potent
dual A1/A2A AR antagonist (Ki, human receptors, A1: 249 nM,
A2A: 253 nM), while compound 9b is a moderately potent
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FIGURE 2 | Structures and Ki/IC50 values of dual A2A AR antagonists/MAO-B inhibitors and dual A1/A2A AR antagonists (r, rat; h, human).
triple-target A1/A2A AR antagonist/MAO-B inhibitor with Ki-
/IC50-values of 605, 417, and 1,800 nM, respectively. However,
a major drawback of this class of compounds is their low
water-solubility, similar to that of many xanthines such as
3. In continuation of our efforts to develop improved, more
water-soluble A2A AR antagonists, structures 10 had been
designed (Figure 3; Brunschweiger et al., 2014, 2016). In 10,
the nitrogen atom in position 9 of the tricyclic structures 9 was
(formally) shifted to position 8. Consequently, the nitrogen
atom is much more basic, and compounds 10 display improved
water-solubility at physiological pH values. Several compounds
of this series showed triple-target inhibition, one of the best
derivatives being 8-(2,4-dichloro-5-fluorobenzyl)-1,3-dimethyl-
6,7,8,9-tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-dione (10a,
human receptors: Ki A1: 217 nM, Ki A2A: 268 nM, IC50 human
MAO-B: 508 nM). 8-(3,4-Dichlorobenzyl)-1,3-dimethyl-6,7,8,9-
tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-dione (10b) was
the best triple-target drug in rat (Ki rat receptors A1: 351 nM,
A2A: 322 nM, IC50 rat MAO-B: 260 nM) and should therefore
be a suitable tool for animal studies. 1,3-Dimethyl-6,7,8,9-
tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-dione (10c, Ki,
human receptors, A1: 116 nM, A2A: 94 nM) was identified as a
potent dual A1/A2AR antagonist.
In the present study, we report on the synthesis of a series of
64 novel tetrahydropyrazino[2,1-f ]purinedione derivatives 11–
20. The final products 13–20 were evaluated as antagonists at
all four AR subtypes (A1, A2A, A2B, A3) and as inhibitors of
both MAO isoenzymes (MAO-A and MAO-B). Substituents on
positions N1, N3 and N8 were varied in order to modulate
the biological activities of the compounds (Figure 4). Differently
substituted benzyl and phenethyl residues were introduced
at position 8 keeping the nitrogen atom N8 basic to allow
for protonation. In order to study the effects of substituents
at nitrogen atoms N1 and N3 on the biological activity of
the compounds, methyl groups found in caffeine derivatives
and in the majority of published tetrahydropyrazino[2,1-
f ]purinediones were replaced by ethyl, propyl, cyclopropyl, or
propargyl (prop-2-yn-1-yl) moieties, or remained unsubstituted.
Within the series of 1-ethyl-3-propargyl-tetrahydropyrazino[2,1-
f ]purine-2,4(1H,3H)-diones 20 phenyl residues bearing different
substituents were additionally introduced in position 8 for
comparison with benzyl- and phenethyl-substituted derivatives.
MATERIALS AND METHODS
General Information
All commercially available reagents and solvents were used
without further purification. The reactions were monitored
by thin layer chromatography (TLC) using aluminum sheets
coated with silica gel 60 F254 (Merck). Melting points were
determined on a Büchi 530 melting point apparatus and are
uncorrected. Column chromatography was carried out on silica
gel 0.040–0.063mm using a Sepacore flash chromatography
system (Büchi). 1H NMR and 13C NMR data were recorded on
a Bruker Avance spectrometer at 500 MHz for proton and 125
MHz for carbon at ambient temperature (for 13C NMR data, see
Supplementary Materials). Shifts are given in ppm relative to the
remaining protons of the deuterated solvents. The purity of the
tested compounds was determined by HPLC-UV obtained on an
LC-MS instrument (Applied Biosystems API 2000 LC-MS/MS,
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FIGURE 3 | Structures and Ki/IC50 values of tetrahydropyrimido[2,1-f ]purinediones (9a,b) and tetrahydropyrazino[2,1-f ]purinediones (10a,b,c) as dual- and
multi-target drugs (r, rat; h, human).
HPLC Agilent 1100) using the procedure as follows: dissolving
of the compounds at a concentration of 1.0mg/mL in methanol
and if necessary sonication to complete dissolution. Then, 10
µL of the substance solution was injected into a Phenomenex
Luna C18 HPLC column (50 × 2.00mm, particle size 3µm)
and elution was performed for 30min at a flow rate of 250
µL/min with a gradient of water: methanol either containing
2mM ammonium acetate from 90:10 up to 0:100, starting the
gradient after 10min (systemA) or containing 2mM ammonium
acetate and 0.1% formic acid from 90:10 up to 0:100, starting the
gradient after 10min (system B). UV absorption was detected
from 220 to 400 nm using a diode array detector. Mass spectra
were recorded on an API 2000 mass spectrometer (electron spray
ion source, Applied Biosystems, Darmstadt, Germany) coupled
with an Agilent 1100 HPLC system.
Synthesis of Final Compounds
General Procedure for the Preparation of
8-substituted 6,7,8,9-tetrahydropyrazino[2,1-f]
purine-2,4(1H,3H)-diones 13–15 (General
Procedure A)
7-(2-Bromoethyl)-8-hydroxymethylpurine-2,4-dione 23c, 23d or
23e (400mg) was dissolved in dry CH2Cl2 (50mL). The solution
was cooled to 0◦C and PBr3 (0.4mL) was added dropwise. The
reaction mixture was allowed to warm to rt and stirred for 1 h.
FIGURE 4 | Structural modifications introduced into new
tetrahydropyrazino[2,1-f ]purinedione derivatives.
Then it was cooled to 0◦C again. To hydrolyze the excess of
PBr3, saturated aq. NaHCO3-solution (5mL) was added and the
pH was set to 7–8 by addition of NaHCO3. Then, the lower
layer was separated in a separating funnel and the aqueous layer
was extracted with CH2Cl2 (2 × 50mL). The organic extracts
were combined, dried over Na2SO4 and the solvent was removed
by rotary evaporation. The residue was dissolved in a mixture
of dimethoxyethane (10mL) and DIPEA (0.5mL). To effect
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ring closing reaction, an appropriate amine was added and the
solution was stirred overnight at rt. The volatiles were removed
by rotary evaporation and the product precipitated upon addition
of H2O (20mL). For purification, the compound was either
filtered off and washed with H2O (3 × 5mL) and diethylether
(3 × 10mL) or subjected to flash-chromatography (silica gel,
CH2Cl2:MeOH 1:0 to 40:1).
8-(2-Bromobenzyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13a)
General procedure A. Yield: 83%; mp: 289◦C; 1H-NMR (CDCl3)
δ 7.55 (dd, 3J = 8.20Hz, 4J = 1.25Hz, 1H, H-3, phenyl), 7.44
(d, 3J = 7.25Hz, 1H, H-6, phenyl), 7.28 (ddd, 3J = 7.60Hz, 3J =
8.55Hz, 4J = 1.60Hz, 1H, H-4, phenyl), 7.14 (dd, 3J = 7.55Hz,
3J = 7.55Hz, 1H, H-5, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2 ×
H-6), 3.86 (s, 2H, N8-CH2), 3.83 (s, 2H, 2 × H-9), 3.51 (s, 3H,
N1-CH3), 3.02 (t, 3J = 5.40Hz, 2H, 2 × H-7). ESI-MS: positive
mode 390.3 and 392.3 [M+H]+. HPLC: 99.9% (A) and 99.6% (B).
1-Methyl-8-(3-(trifluoromethyl)benzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13b)
General procedure A. Yield: 65%; mp: 215◦C; 1H-NMR (CDCl3)
δ 9.41 (s, 1H, N3-H), 7.59 (br s, 1H, H-2, phenyl), 7.53–7.51 (m,
2H, H-5 and H-6, phenyl), 7.45–7.42 (m, 1H, H-4, phenyl), 4.32
(t, 3J = 5.35Hz, 2H, 2×H-6), 3.77 (s, 2H, N8-CH2), 3.73 (s, 2H,
2 × H-9), 3.45 (s, 3H, N1-CH3), 2.94 (t, 3J = 5.35Hz, 2H, 2 ×
H-7). ESI-MS: positive mode 380.4 [M+H]+. HPLC: 99.4% (A)
and 99.9% (B).
8-(3-Chlorophenethyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13c)
General procedure A. Yield: 62%; mp: 228◦C; 1H-NMR (CDCl3)
δ 8.11 (s, 1H, N3-H), 7.21–7.18 (m, 3H, H-2, H-4 and H-5,
phenyl), 7.09–7.07 (m, 2H, H-6, phenyl), 4.30 (t, 3J = 5.35Hz,
2H, 2 × H-6), 3.81 (s, 2H, 2 × H-9), 3.53 (s, 3H, N1-CH3), 2.96
(t, 3J = 5.35Hz, 2H, 2 × H-7), 2.83 (s, 4H, N8-CH2-CH2). ESI-
MS: negativemode 358.0 [M-H]−, positivemode 360.3 [M+H]+.
HPLC: 98.8% (A) and 98.9% (B).
8-(3-Bromophenethyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13d)
General procedure A. Yield: 71%; mp: 240◦C; 1H-NMR (CDCl3)
δ 8.09 (s, 1H, N3-H), 7.35–7.33 (m, 2H, H-2 and H-5, phenyl),
7.17–7.11 (m, 2H, H-4 and H-6, phenyl), 4.30 (t, 3J = 5.35Hz,
2H, 2 × H-6), 3.81 (s, 2H, 2 × H-9), 3.53 (s, 3H, N1-CH3),
2.97 (br s, 2H, 2 × H-7), 2.84 (br s, 4H, N8-CH2-CH2). ESI-
MS: negativemode 404.0 [M-H]−, positivemode 406.4 [M+H]+.
HPLC: 97.5% (A) and 97.5% (B).
1-Methyl-8-(3-(trifluoromethyl)phenethyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13e)
General procedure A. Yield: 63%; mp: 252◦C; 1H-NMR (CDCl3)
δ 8.10 (s, 1H, N3-H), 7.46 (d, 4J = 1.60Hz, 1H, H-2, phenyl),
7.46–7.44 (m, 1H, H-5, phenyl), 7.38–7.35 (m, 2H, H-4 and H-
6, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6), 3.83 (s, 2H, 2 ×
H-9), 3.53 (s, 3H, N1-CH3), 2.98 (t, 3J = 5.35Hz, 2H, 2 × H-7),
2.92–2.84 (m, 4H, N8-CH2-CH2). ESI-MS: negative mode 392.0
[M-H]−, positive mode 394.4 [M+H]+. HPLC: 97.7% (A) and
97.6% (B).
8-(2,4-Dichlorophenethyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13f)
General procedure A. Yield: 55%; mp: 260◦C; 1H-NMR (CDCl3)
δ 7.35 (s, 1H, H-3, phenyl), 7.17 (d, 3J = 7.90Hz, 2H, H-5 and
H-6, phenyl), 4.34 (br s, 2H, 2×H-6), 3.87 (s, 2H, 2×H-9), 3.53
(s, 3H, N1-CH3), 3.02 (br s, 2H, 2 × H-7), 2.97 (t, 3J = 6.90Hz,
2H, N8-CH2), 2.84 (t, 3J = 7.25Hz, 2H, N8-CH2-CH2). ESI-
MS: negativemode 392.0 [M-H]−, positivemode 394.4 [M+H]+.
HPLC: 95.0% (A) and 95.2% (B).
8-(3,4-Dichlorophenethyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13g)
General procedure A. Yield: 69%; mp: 241◦C; 1H-NMR (CDCl3)
δ 7.33 (d, 3J = 8.15Hz, 1H, H-5, phenyl), 7.29 (d, 4J = 1.90Hz,
1H, H-2, phenyl), 7.02 (dd, 3J = 8.15Hz, 4J = 2.25Hz, 1H, H-6,
phenyl), 4.34 (t, 3J = 5.05Hz, 2H, 2 × H-6), 3.81 (s, 2H, 2 × H-
9), 3.54 (s, 3H, N1-CH3), 2.97 (t, 3J = 5.05Hz, 2H, 2×H-7), 2.82
(br s, 4H, N8-CH2-CH2). ESI-MS: negative mode 392.0 [M-H]−,
positive mode 394.3 [M+H]+. HPLC: 99.9% (A) and 99.1% (B).
8-(3,4-Dichlorophenethyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13h)
General procedure A. Yield: 56%; mp: 276◦C; 1H-NMR (DMSO-
d6) δ 11.01 (s, 1H, N1-H), 7.63 (d, 4J = 1.9Hz, 1H, H-2, phenyl),
7.61 (d, 4J = 8.2Hz, 1H, H-4, phenyl), 7.37 (dd, 3J = 8.2Hz, 4J =
1.9Hz, 1H, H-5, phenyl), 4.18 (t, J=5.4Hz, 2H, 2×H-6), 3.75 (s,
2H, N8-CH2), 3.73 (s, 2H, 2 × H-9), 3.31 (s, 3H, N1-CH3), 2.92
(t, 2H, 2× H-7). ESI-MS: negative mode 378.3 [M-H]−, positive
mode 380.1 [M+H]+. HPLC: 99.2% (C).
8-(2-Chloro-5-(trifluoromethyl)benzyl)-1-methyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (13i)
General procedure A. Yield: 71%; mp: 253◦C; 1H-NMR (CDCl3)
δ 7.74 (s, 1H, H-6, phenyl), 7.49 (2 × d, 3J = 8.50Hz, 2H, H-3
and H-4, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×H-6), 3.89 (s, 2H,
N8-CH2), 3.82 (s, 2H, 2× H-9), 3.53 (s, 3H, N1-CH3), 3.02 (t, 3J
= 5.35Hz, 2H, 2×H-7). ESI-MS: positive mode 414.3 [M+H]+.
HPLC: 97.1% (A) and 97.4% (B).
8-(2-Bromobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14a)
General Procedure A. Yield: 75%; mp: 224◦C; 1H-NMR (CDCl3)
δ 7.55 (dd, 3J= 8.20Hz, 4J= 1.25Hz, 1H,H-3, phenyl), 7.44 (d, 3J
= 7.65Hz, 4J = 1.65Hz, 1H, H-6, phenyl), 7.30–7.27 (m, 1H, H-
4, phenyl), 7.16–7.13 (m, 1H, H-5, phenyl), 4.35 (t, 3J = 5.35Hz,
2H, 2 × H-6), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.86 (s, 2H,
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N8-CH2), 3.83 (s, 2H, 2 × H-9), 3.51 (s, 3H, N1-CH3), 3.02 (t,
3J = 5.40Hz, 2H, 2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-
CH3). ESI-MS: positive mode 418.3 and 420.3 [M+H]+. HPLC:
98.4% (A) and 99.0% (B).
8-(3-Bromobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14b)
General Procedure A. Yield: 81%; mp: 194◦C; 1H-NMR (CDCl3)
δ 7.50 (s, 1H, H-2, phenyl), 7.42–7.40 (m, 1H, H-4, phenyl),
7.26–7.23 (m, 1H, H-6, phenyl), 7.21–7.18 (m, 1H, H-5,
phenyl), 4.55 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.04 (q, 3J
= 6.90Hz, 2H, N3-CH2), 3.93 (br s, 4H, N8-CH2, 2 ×
H-9), 3.52 (s, 3H, N1-CH3), 3.18 (t, 3J = 5.05Hz, 2H, 2
× H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 418.3 and 420.3 [M+H]+. HPLC: 99.7% (A) and
99.9% (B).
8-(4-Bromobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14c)
General Procedure A. Yield: 42%; mp: 156◦C; 1H-NMR (CDCl3)
δ 7.45 (d, 3J = 8.20Hz, 2H, H-3 and H-5, phenyl), 7.44 (d, 3J =
8.20Hz, 2H, H-2 and H-6, phenyl), 4.32 (t, 3J = 5.35Hz, 2H, 2×
H-6), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.72 (s, 2H, N8-CH2),
3.67 (s, 2H, 2×H-9), 3.51 (s, 3H, N1-CH3), 2.92 (t, 3J = 5.35Hz,
2H, 2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 418.3 and 420.3 [M+H]+. HPLC: 98.7% (A) and
99.5% (B).
3-Ethyl-1-methyl-8-(2-(trifluoromethyl)benzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14d)
General Procedure A. Yield: 60%; mp: 182◦C; 1H-NMR (CDCl3)
δ 7.72 (d, 3J = 7.75Hz, 1H, H-6, phenyl), 7.66 (d, 3J = 7.80Hz,
1H, H-3, phenyl), 7.53 (dd, 3J = 7.60Hz, 3J = 7.20Hz, 1H,
H-5, phenyl), 7.39 (dd, 3J = 7.60Hz, 3J = 7.65Hz, 1H, H-
4, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.04 (q, 3J
= 6.90Hz, 2H, N3-CH2), 3.90 (s, 2H, N8-CH2), 3.78 (s, 2H,
2 × H-9), 3.51 (s, 3H, N1-CH3), 2.97 (t, 3J = 5.85Hz, 2H,
2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-
MS: positive mode 408.1 [M+H]+. HPLC: 99.9% (A) and
99.0% (B).
3-Ethyl-1-methyl-8-(3-(trifluoromethyl)benzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14e)
General Procedure A. Yield: 65%; mp: 198◦C; 1H-NMR (CDCl3)
δ 7.60 (s, 1H, H-2, phenyl), 7.58–7.52 (m, 1H, H-5 and H-6,
phenyl), 7.47–7.44 (m, 1H, H-4, phenyl), 4.47 (t, 3J = 5.35Hz,
2H, 2 × H-6), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2), 4.03 (s, 2H,
N8-CH2), 3.84 (s, 2H, 2 × H-9), 3.51 (s, 3H, N1-CH3), 3.08 (t,
3J = 5.35Hz, 2H, 2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-
CH3). ESI-MS: positive mode 408.4 [M+H]+. HPLC: 98.4% (A)
and 99.6% (B).
3-Ethyl-1-methyl-8-(4-(trifluoromethyl)benzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14f)
General Procedure A. Yield: 44%; mp: 162◦C; 1H-NMR (CDCl3)
δ 8.00 (d, 3J = 8.50Hz, 2H, H-3 and H-5, phenyl), 7.64 (d, 3J =
8.50Hz, 2H, H-2 and H-6, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×
H-6), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.96 (s, 2H, N8-CH2),
3.87 (s, 2H, 2×H-9), 3.48 (s, 3H, N1-CH3), 3.05 (t, 3J = 5.40Hz,
2H, 2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 408.3 [M+H]+. HPLC: 99.9% (A) and 99.0% (B).
3-Ethyl-8-(3-fluorobenzyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14g)
General Procedure A. Yield: 54%; mp: 154◦C; 1H-NMR (CDCl3)
δ 7.31–7.27 (m, 1H, H-5, phenyl), 7.10 (d, 3J = 7.60Hz, 1H, H-2,
phenyl), 7.08–7.05 (m, 1H, H-6, phenyl), 7.00–6.96 (m, 1H, H-
4, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.04 (q, 3J =
6.90Hz, 2H, N3-CH2), 3.71 (br s, 4H, N8-CH2 and 2 × H-9),
3.51 (s, 3H, N1-CH3), 2.93 (t, 3J = 5.70Hz, 2H, 2×H-7), 1.21 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 358.3
[M+H]+. HPLC: 98.2% (A) and 99.5% (B).
3-Ethyl-8-(4-fluorobenzyl)-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14h)
General Procedure A. Yield: 33%; mp: 158◦C; 1H-NMR (CDCl3)
δ 7.30–7.28 (m, 2H, H-2 and H-6, phenyl), 7.03–7.00 (m, 2H, H-3
and H-5, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.04 (q, 3J
= 6.90Hz, 2H, N3-CH2), 3.72 (s, 2H, N8-CH2), 3.71 (s, 2H, 2 ×
H-9), 3.51 (s, 3H, N1-CH3), 2.94 (t, 3J = 5.45Hz, 2H, 2 × H-7),
1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode
358.3 [M+H]+. HPLC: 99.2% (A) and 98.4% (B).
8-(3-Chlorobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (14i)
General Procedure A. Yield: 74%; mp: 202◦C; 1H-NMR (CDCl3)
δ 7.34 (d, 4J = 1.25Hz, 1H, H-2, phenyl), 7.27–7.26 (m, 2H, H-
4 and H-6, phenyl), 7.21–7.19 (m, 1H, H-5, phenyl), 4.81 (t, 3J
= 5.00Hz, 2H, 2 × H-6), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2),
3.83 (br s, 4H, N8-CH2, 2 × H-9), 3.53 (s, 3H, N1-CH3), 3.38 (t,
3J = 5.35Hz, 2H, 2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-
CH3). ESI-MS: positive mode 374.3 [M+H]+. HPLC: 99.9% (A)
and 99.9% (B).
8-(2,5-Dichlorobenzyl)-3-ethyl-1-dimethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (14j)
General Procedure A. Yield: 80%; mp: 165◦C; 1H-NMR (CDCl3)
δ 7.44 (d, 4J = 2.50Hz, 1H, H-6, phenyl), 7.30 (d, 3J = 8.50Hz,
1H, H-3, phenyl), 7.20 (dd, 3J = 8.50Hz, 4J = 2.50Hz, 1H, H-4,
phenyl), 4.36 (t, 3J = 5.35Hz, 2H, 2×H-6), 4.04 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.86 (s, 2H, N8-CH2), 3.84 (s, 2H, 2 × H-9), 3.52
(s, 3H, N1-CH3), 3.04 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.21 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 409.3
[M+H]+. HPLC: 98.6% (A) and 99.1% (B).
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8-(2,6-Dichlorobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14k)
General Procedure A. Yield: 64%; mp: 210◦C; 1H-NMR (CDCl3)
δ 7.33 (d, 3J = 8.40Hz, 2H, H-3 and H-5, phenyl), 7.18 (dd, 3J
= 8.40Hz, 1H, H-4, phenyl), 4.38 (t, 3J = 5.35Hz, 2H, 2× H-6),
4.04 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.91 (s, 2H, N8-CH2), 3.83 (s,
2H, 2×H-9), 3.53 (s, 3H, N1-CH3), 3.02 (t, 3J = 5.35Hz, 2H, 2×
H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 394.1 [M+H]+. HPLC: 99.0% (A) and 99.0% (B).
3-Ethyl-8-(2-fluoro-3-(trifluoromethyl)benzyl)-1-
methyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-
2,4(1H,3H)-dione (14l)
General Procedure A. Yield: 42%; mp: 178◦C; 1H-NMR (CDCl3)
δ 7.63–7.60 (m, 1H,H-4, phenyl), 7.57–7.54 (m, 1H,H-5, phenyl),
7.25–7.22 (m, 1H, H-6, phenyl), 4.45 (t, 3J = 5.05Hz, 2H, 2×H-
6), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.97 (s, 2H, N8-CH2),
3.88 (s, 2H, 2×H-9), 3.53 (s, 3H, N1-CH3), 3.11 (t, 3J = 5.35Hz,
2H, 2 × H-7), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 426.3 [M+H]+. HPLC: 98.4% (A) and 98.4% (B).
8-(2-Chloro-5-(trifluoromethyl)benzyl)-3-ethyl-1-
methyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-
2,4(1H,3H)-dione (14m)
General Procedure A. Yield: 64%; mp: 172◦C; 1H-NMR (CDCl3)
δ 7.74 (s, 1H, H-6, phenyl), 7.50–7.49 (m, 2H, H-3 and H-4,
phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×H-6), 4.05 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.89 (s, 2H, N8-CH2), 3.82 (s, 2H, 2 × H-9), 3.53
(s, 3H, N1-CH3), 3.02 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.22 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 442.3
[M+H]+. HPLC: 99.6% (A) and 98.9% (B).
8-(3-Chloro-5-fluorobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14n)
General Procedure A. Yield: 81%; mp: 171◦C; 1H-NMR (CDCl3)
δ 7.15 (s, 1H, H-2, phenyl), 7.02 (d, 3JH,F = 8.20Hz, 1H, H-4,
phenyl), 7.00 (d, 3JH,F = 9.45Hz, 1H, H-6, phenyl), 4.37 (t, 3J =
5.35Hz, 2H, 2 × H-6), 4.05 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.76
(s, 2H, N8-CH2), 3.72 (s, 2H, 2 × H-9), 3.52 (s, 3H, N1-CH3),
2.98 (t, 3J = 5.35Hz, 2H, 2×H-7), 1.22 (t, 3J = 7.25Hz, 3H, N3-
CH2-CH3). ESI-MS: positivemode 392.2 [M+H]+. HPLC: 99.7%
(A) and 99.1% (B).
8-(5-Bromo-2-fluorobenzyl)-3-ethyl-1-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14o)
General Procedure A. Yield: 71%; mp: 208◦C; 1H-NMR (CDCl3)
δ 7.52–7.50 (m, 1H,H-4, phenyl), 7.39–7.35 (m, 1H,H-6, phenyl),
6.96–6.92 (m, 1H, H-3, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×H-
6), 4.05 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.76 (s, 4H, N8-CH2 and
2 × H-9), 3.52 (s, 3H, N1-CH3), 2.98 (t, 3J = 5.35Hz, 2H, 2 ×
H-7), 1.22 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 436.0 and 438.0 [M+H]+. HPLC: 96.4% (A) and 98.5% (B).
3-Ethyl-8-(3-fluoro-5-(trifluoromethyl)benzyl)-1-
methyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-
2,4(1H,3H)-dione (14p)
General Procedure A. Yield: 66%; mp: 166◦C; 1H-NMR (CDCl3)
δ 7.41 (br s, 1H, H-6, phenyl), 7.29–7.25 (m, 2H, H-2 and H-4,
phenyl), 4.37 (t, 3J = 5.05Hz, 2H, 2×H-6), 4.05 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.78 (s, 2H, N8-CH2), 3.74 (s, 2H, 2 × H-9), 3.51
(s, 3H, N1-CH3), 2.97 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.22 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 426.3
[M+H]+. HPLC: 98.4% (A) and 99.6% (B).
8-(3,5-Bis(trifluoromethyl)benzyl)-3-ethyl-1-methyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (14q)
General Procedure A. Yield: 51%; mp: 236◦C; 1H-NMR (CDCl3)
δ 7.81 (s, 2H, H-2 and H-6, phenyl), 7.80 (s, 1H, H-4, phenyl),
4.37 (t, 3J = 5.05Hz, 2H, 2 × H-6), 4.05 (q, 3J = 6.90Hz, 2H,
N3-CH2), 3.85 (s, 2H, N8-CH2), 3.76 (s, 2H, 2 × H-9), 3.53
(s, 3H, N1-CH3), 2.99 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.22 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 476.1
[M+H]+. HPLC: 99.9% (A) and 99.1% (B).
1,3-Diethyl-8-(2-fluorobenzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15a)
General procedure A. Yield: 55%; mp: 143◦C; 1H-NMR (CDCl3)
δ 7.35 (dd, 3J = 7.55Hz, 3J = 5.95Hz, 4J = 1.90Hz, 4JH,F =
5.95Hz, 1H, H-4, phenyl), 7.27 (ddd, 3J = 5.95Hz, 4J = 1.85Hz,
3JH,F = 9.45Hz, 1H, H-3, phenyl), 7.07 (dd, 3J = 6.25Hz, 4J =
1.30Hz, 1H, H-6, phenyl), 7.02 (pseudo-t, 3J = 8.55Hz, 3J =
5.95Hz, 2H, H-5, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6),
4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz, 2H,
N3-CH2), 3.81 (s, 2H, N8-CH2), 3.77 (s, 2H, 2 × H-9), 2.97 (t,
3J = 5.35Hz, 2H, 2 × H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 372.2 [M+H]+. HPLC: 98.1% (A) and 98.5% (B).
1,3-Diethyl-8-(3-fluorobenzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15b)
General procedure A. Yield: 62%; mp: 145◦C; 1H-NMR (CDCl3)
δ 7.30 (dd, 3J = 7.90Hz, 4J = 1.90Hz, 1H, H-5, phenyl), 7.08
(pseudo-t, 3J = 7.90Hz, 3J = 8.20Hz, 1H, H-4, phenyl), 7.06 (d,
3J = 8.20Hz, 1H, H-6, phenyl), 6.98 (m, 1H, 3J = 7.55Hz, 4J =
2.20Hz, 3JH,F = 9.80Hz, H-2, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2
×H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.76 (s, 2H, N8-CH2), 3.71 (s, 2H, 2 × H-9), 2.93
(t, 3J = 5.70Hz, 2H, 2×H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 372.1 [M+H]+. HPLC: 99.8% (A) and 99.9% (B).
8-(3-Chlorobenzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15c)
General procedure A. Yield: 68%; mp: 153◦C; 1H-NMR (CDCl3)
δ 7.35–7.34 (m, 1H, H-2, phenyl), 7.27–7.26 (m, 2H, H-5 and H-
6, phenyl), 7.22–7.20 (m, 1H, H-4, phenyl), 4.35 (t, 3J = 5.00Hz,
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2H, 2 × H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J =
6.90Hz, 2H, N3-CH2), 3.83 (br s, 4H, N-8-CH2, 2 × H-9), 3.38
(t, 3J = 5.35Hz, 2H, 2×H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 388.3 [M+H]+. HPLC: 99.7% (A) and 99.0% (B).
8-(3-Bromobenzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15d)
General procedure A. Yield: 81%; mp: 135◦C; 1H-NMR (CDCl3)
δ 7.50 (s, 1H, H-2, phenyl), 7.51 (dd, 3J = 8.20Hz, 4J = 1.20Hz,
1H, H-4, phenyl), 7.42 (d, 3J = 6.90Hz, 1H, H-6, phenyl), 7.24
(pseudo-t, 3J = 7.90Hz, 3J = 7.55Hz, 1H, H-5, phenyl), 7.19 (dd,
3J= 7.55Hz, 3J= 7.55Hz, 1H, H-5, phenyl), 4.55 (t, 3J= 5.35Hz,
2H, 2 × H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J =
6.90Hz, 2H, N3-CH2), 3.72 (s, 2H, N8-CH2), 3.69 (s, 2H, 2×H-
9), 2.94 (t, 3J = 5.05Hz, 2H, 2 × H-7), 1.29 (t, 3J = 7.25Hz, 3H,
N1-CH2-CH3), 1.22 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 432.0 and 434.0 [M+H]+. HPLC: 99.7% (A) and
99.9% (B).
8-(4-Bromobenzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15e)
General procedure A. Yield: 48%; mp: 140◦C; 1H-NMR (CDCl3)
δ 7.45 (d, 3J = 8.20Hz, 2H, H-3 and H-5, phenyl), 7.21 (d, 3J =
8.20Hz, 2H, H-2 and H-6, phenyl), 4.32 (t, 3J = 5.35Hz, 2H, 2×
H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.72 (s, 2H, N8-CH2), 3.67 (s, 2H, 2 × H-9), 2.92
(t, 3J = 5.35Hz, 2H, 2×H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 432.0 and 434.0 [M+H]+. HPLC: 99.9% (A) and 99.7% (B).
1,3-Diethyl-8-(2-(trifluoromethyl)benzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15f)
General procedure A. Yield: 63%; mp: 142◦C; 1H-NMR (CDCl3)
δ 7.72 (d, 3J = 7.80Hz, 1H, H-6, phenyl), 7.65 (d, 3J = 7.80Hz,
1H, H-2, phenyl), 7.73 (dd, 3J = 7.50Hz, 3J = 7.50Hz, 1H, H-5,
phenyl), 7.65 (dd, 3J = 7.60Hz, 3J = 7.70Hz, 1H, H-4, phenyl),
4.33 (t, 3J = 5.35Hz, 2H, 2×H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-
CH2), 4.04 (q, 3J = 7.25Hz, 2H, N3-CH2), 3.90 (s, 2H, N8-CH2),
3.78 (s, 2H, 2×H-9), 2.97 (t, 3J = 5.85Hz, 2H, 2×H-7), 1.29 (t,
3J = 7.25Hz, 3H, N1-CH2-CH3), 1.22 (t, 3J = 7.25Hz, 3H, N3-
CH2-CH3). ESI-MS: positivemode 422.0 [M+H]+. HPLC: 99.9%
(A) and 99.3% (B).
1,3-Diethyl-8-(3-(trifluoromethyl)benzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15g)
General Procedure A. Yield: 60%; mp: 124◦C; 1H-NMR (CDCl3)
δ 7.60 (br s, 2H, H-2, phenyl), 7.55–7.52 (m, 2H, H-5 and H-6,
phenyl), 7.47–7.44 (m, 1H, H-4, phenyl), 4.35 (t, 3J = 5.35Hz,
2H, 2 × H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J =
7.25Hz, 2H, N3-CH2), 3.78 (s, 2H, N8-CH2), 3.73 (s, 2H, 2×H-
9), 2.95 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.30 (t, 3J = 7.25Hz, 3H,
N1-CH2-CH3), 1.21 (3H, t, 3J = 7.25Hz, N3-CH2-CH3). ESI-MS:
positive mode 422.0 [M+H]+. HPLC: 99.8% (A) and 99.4% (B).
1,3-Diethyl-8-(2-fluoro-3-(trifluoromethyl)benzyl)-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15h)
General Procedure A. Yield: 35%; mp: 162◦C; 1H-NMR (CDCl3)
δ 7.63–7.60 (m, 1H,H-4, phenyl), 7.58–7.55 (m, 1H,H-5, phenyl),
7.26–7.23 (m, 1H, H-6, phenyl), 4.45 (t, 3J = 5.05Hz, 2H, 2×H-
6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz, 2H,
N3-CH2), 3.97 (s, 2H, N8-CH2), 3.88 (s, 2H, 2 × H-9), 3.11 (t,
3J = 5.35Hz, 2H, 2 × H-7), 1.30 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.22 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 440.4 [M+H]+. HPLC: 99.5% (A) and 99.9% (B).
1,3-Diethyl-8-(4-fluoro-3-(trifluoromethyl)benzyl)-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15i)
General Procedure A. Yield: 66%; mp: 171◦C; 1H-NMR (CDCl3)
δ 7.60–7.58 (m, 1H,H-6, phenyl), 7.54–7.51 (m, 1H,H-2, phenyl),
7.19–7.16 (m, 1H, H-5, phenyl), 4.34 (t, 3J = 5.05Hz, 2H, 2×H-
6), 4.10 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz, 2H,
N3-CH2), 3.74 (s, 2H, N8-CH2), 3.72 (s, 2H, 2 × H-9), 2.95 (t,
3J = 5.35Hz, 2H, 2 × H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.22 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 440.3 [M+H]+. HPLC: 99.5% (A) and 99.0% (B).
1,3-Diethyl-8-(2-fluoro-5-(trifluoromethyl)benzyl)-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15j)
General Procedure A. Yield: 73%; mp: 154◦C; 1H-NMR (CDCl3)
δ 7.70–7.69 (m, 1H,H-6, phenyl), 7.58–7.55 (m, 1H,H-4, phenyl),
7.20–7.16 (m, 1H, H-3, phenyl), 4.36 (t, 3J = 5.35Hz, 2H, 2×H-
6), 4.10 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.87 (s, 2H, N8-CH2), 3.81 (s, 2H, 2 × H-9), 3.52
(s, 3H, N1-CH3), 3.37 (s, 3H, N3-CH3), 3.02 (t, 3J = 5.35Hz,
2H, 2 × H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3), 1.22 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 440.3
[M+H]+. HPLC: 99.9% (A) and 99.9% (B).
8-(3-Bromo-4-fluorobenzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15k)
General Procedure A. Yield: 44%; mp: 156◦C; 1H-NMR (CDCl3)
δ 7.56–7.54 (m, 1H,H-2, phenyl), 7.26–7.23 (m, 1H,H-6, phenyl),
7.10–7.06 (m, 1H, H-5, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×H-
6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz, 2H,
N3-CH2), 3.75 (s, 2H, N8-CH2), 3.72 (s, 2H, 2 × H-9), 3.37 (s,
3H, N3-CH3), 2.98 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.29 (t, 3J =
7.25Hz, 3H, N1-CH2-CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-
CH3). ESI-MS: positive mode 450.3 and 452.3 [M+H]+. HPLC:
99.5% (A) and 99.5% (B).
8-(5-Bromo-2-fluorobenzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (15l)
General Procedure A. Yield: 70%; mp: 190◦C; 1H-NMR (CDCl3)
δ 7.53–7.51 (m, 1H,H-4, phenyl), 7.40–7.37 (m, 1H,H-6, phenyl),
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6.97–6.93 (m, 1H, H-3, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×H-
6), 4.10 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz,
2H, N3-CH2), 3.77 (s, 4H, 2 × H-9 and N8-CH2), 2.98 (t, 3J =
5.35Hz, 2H, 2 × H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3),
1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode
436.0 and 438.0 [M+H]+. HPLC: 99.5% (A) and 99.4% (B).
8-(3,5-Dichlorobenzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15m)
General Procedure A. Yield: 70%; mp: 182◦C; 1H-NMR (CDCl3)
δ 7.28 (d, 4J = 1.90Hz, 1H, H-4, phenyl), 7.24 (d, 4J = 1.90Hz,
2H, H-2 and H-6, phenyl), 4.36 (t, 3J = 5.35Hz, 2H, 2 × H-6),
4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz, 2H,
N3-CH2), 3.73 (s, 2H, N8-CH2), 3.68 (s, 2H, 2 × H-9), 2.95 (t,
3J = 5.35Hz, 2H, 2 × H-7), 1.30 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.22 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 423.3 [M+H]+. HPLC: 98.0% (A) and 99.6% (B).
8-(2-Chloro-5-(trifluoromethyl)benzyl)-1,3-diethyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15n)
General Procedure A. Yield: 60%; mp: 152◦C; 1H-NMR (CDCl3)
δ 7.74 (s, 1H, H-6, phenyl), 7.50–7.49 (m, 2H, H-3 and H-4,
phenyl), 4.38 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.10 (q, 3J =
7.25Hz, 2H, N1-CH2), 4.05 (q, 3J = 6.90Hz, 2H, N3-CH2), 3.89
(s, 2H, N8-CH2), 3.83 (s, 2H, 2 × H-9), 3.01 (t, 3J = 5.35Hz,
2H, 2 × H-7), 1.30 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3), 1.22 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 442.3
[M+H]+. HPLC: 99.5% (A) and 99.4% (B).
8-(4-Chloro-2-(trifluoromethyl)benzyl)-1,3-diethyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15o)
General Procedure A. Yield: 27%; mp: 188◦C; 1H-NMR (CDCl3)
δ 7.69 (d, 3J= 8.55Hz, 1H,H-6, phenyl), 7.64 (dd, 3J= 8.55Hz, 4J
= 1.90Hz, 1H, H-5, phenyl), 7.49 (dd, 3J = 8.55Hz, 4J = 2.20Hz,
1H, H-3, phenyl), 4.34 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.10 (q, 3J
= 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J = 6.90Hz, 2H, N3-CH2),
3.86 (s, 2H, N8-CH2), 3.77 (s, 2H, 2×H-9), 2.95 (t, 3J = 5.35Hz,
2H, 2 × H-7), 1.30 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3), 1.22 (t,
3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive mode 428.0
[M+H]+. HPLC: 98.9% (A) and 99.4% (B).
8-(4-Chloro-3-(trifluoromethyl)benzyl)-1,3-diethyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15p)
General Procedure A. Yield: 38%; mp: 165◦C; 1H-NMR (CDCl3)
δ 7.67 (s, 1H, H-2, phenyl), 7.48 (d, 3J = 8.20Hz, 1H, H-6,
phenyl), 7.45 (d, 3J = 8.20Hz, 1H, H-5, phenyl), 4.35 (t, 3J =
5.05Hz, 2H, 2 × H-6), 4.10 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04
(q, 3J = 6.90Hz, 2H, N3-CH2), 3.76 (s, 2H, N8-CH2), 3.73 (s,
2H, 2 × H-9), 3.51 (s, 3H, N1-CH3), 3.37 (s, 3H, N3-CH3), 2.96
(t, 3J = 5.35Hz, 2H, 2×H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS: positive
mode 456.3 [M+H]+. HPLC: 99.7% (A) and 99.7% (B).
8-(3,5-Bis(trifluoromethyl)benzyl)-1,3-diethyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15q)
General Procedure A. Yield: 51%; mp: 141◦C; 1H-NMR (CDCl3)
δ 7.81 (br s, 3H, H-2, H-4 and H-6, phenyl), 4.37 (t, 3J = 5.05Hz,
2H, 2 × H-6), 4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J =
6.90Hz, 2H, N3-CH2), 3.85 (s, 2H, N8-CH2), 3.76 (s, 2H, 2×H-
9), 2.99 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.29 (t, 3J = 7.25Hz, 3H,
N1-CH2-CH3), 1.21 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 490.4 [M+H]+. HPLC: 99.7% (A) and 99.7% (B).
1,3-Diethyl-8-(3,4,5-trifluorobenzyl)-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (15r)
General Procedure A. Yield: 43%; mp: 166◦C; 1H-NMR (CDCl3)
δ 7.00–6.97 (m, 2H, H-2 and H-6, phenyl), 4.33 (t, 3J = 5.35Hz,
2H, 2 × H-6), 4.10 (q, 3J = 7.25Hz, 2H, N1-CH2), 4.04 (q, 3J =
6.90Hz, 2H, N3-CH2), 3.73 (s, 2H, N8-CH2), 3.66 (s, 2H, 2×H-
9), 2.96 (t, 3J = 5.35Hz, 2H, 2 × H-7), 1.30 (t, 3J = 7.25Hz, 3H,
N1-CH2-CH3), 1.22 (t, 3J = 7.25Hz, 3H, N3-CH2-CH3). ESI-MS:
positive mode 408.3 [M+H]+. HPLC: 97.8% (A) and 96.5% (B).
Preparation of 8-Substituted 6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-diones
16–17 via Alkylation of the 3-Position (General
Procedure B)
The 3-unsubstituted tetrahydropyrazino[2,1-f ]purinediones 11a,
11b or 12 (0.25 mmol), potassium tert-butoxide (56mg, 0.5
mmol) and an alkylating agent (1.5 mmol, 6 eq.) were dissolved
in 4mL of dry THF and stirred for 4 h at rt under argon. The
progress of the reaction was checked by TLC after 3 h and, if
necessary, a further 4 eq. of the alkylating agent was added to
drive the reaction to completion. The volatiles were removed
by rotary evaporation and the product was purified by silica
gel column chromatography using a gradient of CH2Cl2 to
CH2Cl2/MeOH 40:1 as eluent.
8-(3,4-Dichlorobenzyl)-1-ethyl-3-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (16a)
General procedure B starting from 11a. Yield: 31%; mp: 164◦C;
1H-NMR (CDCl3) δ 7.44 (d, 4J = 1.90Hz, 1H, H-2, phenyl), 7.39
(d, 3J = 8.20Hz, 1H, H-5, phenyl), 7.17 (dd, 3J = 8.20Hz and 4J
= 2.40Hz, 1H, H-6, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2× H-6),
4.08 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.72 (s, 2H, N8-CH2), 3.68 (s,
2H, 2×H-9), 3.36 (s, 3H, N3-CH3), 2.93 (t, 3J = 5.35Hz, 2H, 2×
H-7), 1.28 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive
mode 408.3 [M+H]+. HPLC: 99.7% (A) and 99.7% (B).
8-(3,5-Dichlorobenzyl)-1-ethyl-3-methyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (16b)
General procedure B starting from 11b. Yield: 32%; mp: 183◦C;
1H-NMR (CDCl3) δ 7.29 (d, 4J = 1.90Hz, 1H, H-4, phenyl), 7.24
(s, 2H, H-2 and H-6, phenyl), 4.35 (t, 3J = 5.35Hz, 2H, 2×H-6),
4.09 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.73 (s, 2H, N8-CH2), 3.68 (s,
2H, 2×H-9), 3.35 (s, 3H, N3-CH3), 2.95 (t, 3J = 5.35Hz, 2H, 2×
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H-7), 1.29 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive
mode 408.3 [M+H]+. HPLC: 99.7% (A) and 99.7% (B).
8-(3,4-Dichlorobenzyl)-1-cyclopropyl-3-methyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (17)
General procedure B starting from 12. Yield: 35%; mp: 200◦C;
1H-NMR (CDCl3) δ 7.44 (d, 4J = 1.85Hz, 1H, H-2, phenyl), 7.40
(d, 3J = 8.20Hz, 1H, H-5, phenyl), 7.16 (dd, 3J = 8.20Hz, 4J =
1.90Hz, 1H, H-6, phenyl), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6),
3.74 (s, 2H, N8-CH2), 3.68 (s, 2H, 2 × H-9), 3.34 (s, 3H, N3-
CH3), 2.94–2.92 (m, 3H, 2 × H-7 and H-1, cyclopropyl), 1.19–
1.12 (m, 2H, H-2 and H-3, cyclopropyl), 1.00–0.96 (m, 2H, H-2
and H-3, cyclopropyl). ESI-MS: positive mode 420.1 [M+H]+.
HPLC: 98.2% (A) and 97.5% (B).
Preparation of 8-Substituted 6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-diones
18–19 via Alkylation of the 3-Position (General
Procedure C)
The 3-unsubstituted tetrahydropyrazino[2,1-f ]purinediones 13h
or 13i (0.25 mmol), sodium hydride (60% in mineral oil) and
the appropriate alkylating agent were dissolved in dry DMF and
stirred for 4 h at rt under argon. The volatiles were removed
by rotary evaporation and the product was purified by flash-
chromatography (silica gel, CH2Cl2: CH2Cl2/MeOH 1:0 to 40:1).
8-(3,4-Dichlorobenzyl)-1-methyl-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (18)
General procedure C starting from 13h. Yield: 43%; mp: 159◦C;
1H-NMR (CDCl3) δ 7.44 (d, 4J = 2.00Hz, 1H, H-2, phenyl), 7.40
(d, 3J = 8.20Hz, 1H, H-5, phenyl), 7.17 (dd, 3J = 8.20Hz, 4J =
2.00Hz, 1H, H-6, phenyl), 4.34 (t, 3J = 5.45Hz, 2H, 2 × H-6),
3.95–3.92 (m, 2H, N3-CH2), 3.72 (s, 2H, N8-CH2), 3.68 (s, 2H,
2 × H-9), 3.51 (s, 3H, N1-CH3), 2.95–2.92 (m, 2H, 2 × H-7),
1.69–1.62 (m, 3H, N3-CH2-CH2), 0.93 (t, 3J = 7.45Hz, 3H, N3-
CH2-CH2-CH3). ESI-MS: positive mode 422.2 [M+H]+. HPLC:
96.9% (C).
8-(3,4-Dichlorobenzyl)-1-methyl-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (19a)
General procedure C starting from 13h. Yield: 58%; mp: 228◦C;
1H-NMR (CDCl3) δ 7.44 (d, 4J = 2.00Hz, 1H, H-2, phenyl), 7.41
(d, 3J = 8.20Hz, 1H, H-5, phenyl), 7.17 (dd, 3J = 8.20Hz, 4J =
2.00Hz, 1H, H-6, phenyl), 4.76 (d, 4J = 2.45Hz, 2H, N3-CH2),
4.35 (t, 3J = 5.45Hz, 2H, 2×H-6), 3.73 (s, 2H, N8-CH2), 3.68 (s,
2H, 2×H-9), 3.53 (s, 3H, N1-CH3), 2.95–2.93 (m, 2H, 2×H-7),
2.15 (t, 4J = 2.45Hz, 1H, N3-CH2-CH). ESI-MS: positive mode
418.2 [M+H]+. HPLC: 98.6% (C).
8-(2-Chloro-5-(trifluoromethyl)benzyl)-1-methyl-3-
propargyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-
2,4(1H,3H)-dione (19b)
General procedure C starting from 13i. Yield: 28%; mp: 211◦C;
1H-NMR (CDCl3) δ 7.73 (s, 1H, H-6, phenyl), 7.50 (2 br s, 2H,
H-3 and H-4, phenyl), 4.76 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.38
(s, 2H, N3-CH2), 3.89 (s, 2H, N8-CH2), 3.83 (s, 2H, 2 × H-9),
3.54 (s, 3H, N1-CH3), 3.02 (t, 3J = 5.35Hz, 2H, 2 × H-7), 2.15
(s, 1H, N3-CH2-CH). ESI-MS: positive mode 442.3 [M+H]+.
HPLC: 98.6% (A) and 98.7% (B).
Synthesis of 8-Substituted
1-Ethyl-3-Propargyl-8-6,7,8,9-tetrahydropyrazino[2,1-
f]purine-2,4(1H,3H)-diones (20) (General Procedure
D)
7-(2-Bromoethyl)-8-N-boc-aminomethyl-3-methyl-1-
propargylxanthine (28) (150mg, 0.33 mmol) was stirred in
a solution of 4N-HCl in dry dioxane (4mL) for 30min at rt.
The deprotected xanthine 29 precipitated upon addition of
diethylether (30mL). It was filtered off, washed with diethylether
(3 × 10mL) and used directly in the next step. The xanthine 29
was dissolved in a mixture of 1,2-dimethoxyethane (10mL) and
DIPEA (0.5mL) and stirred for 6 h at rt. Then, the appropriate
halide (0.5 mmol) was added and the solution was stirred
overnight at rt. The volatiles were removed in vacuo and the final
product 20 was purified by column chromatography.
1-Ethyl-8-(2-fluorophenyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20a)
General procedure D. Yield: 28%; mp: 151◦C; 1H-NMR (CDCl3)
δ 7.03–7.00 (m, 2H, H-3 and H-4, phenyl), 6.95–6.92 (m, 2H, H-
5 and H-6, phenyl), 4.77 (d, 4J = 2.20Hz, 2H, N3-CH2), 4.50 (s,
2H, 2 × H-9), 4.45 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.16 (q, 3J =
7.25Hz, 2H, N1-CH2), 3.71 (t, 3J = 5.35Hz, 2H, 2 × H-7), 2.15
(t, 4J = 2.50Hz, 1H, N3-CH2-CH), 1.35 (t, 3J = 7.25Hz, 3H, N1-
CH2-CH3). ESI-MS: positivemode 368.0 [M+H]+. HPLC: 95.2%
(A) and 95.5% (B).
1-Ethyl-8-(4-fluorophenyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20b)
General procedure D. Yield: 31%; mp: 157◦C; 1H-NMR (CDCl3)
δ 6.83–6.70 (m, 4H, 3J = 8.20Hz, and 4J = 2.20Hz, H-2, H-3, H-
5 and H-6, phenyl), 4.77 (d, 4J = 2.20Hz, 2H, N3-CH2), 4.44 (s,
2H, 2 × H-9), 4.18 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.81 (t, 3J =
5.35Hz, 2H, 2 × H-6), 3.62 (t, 3J = 5.35Hz, 2H, 2 × H-7), 2.15
(t, 4J = 2.50Hz, 1H, N3-CH2-CH), 1.35 (t, 3J = 7.25Hz, 3H, N1-
CH2-CH3). ESI-MS: positivemode 368.0 [M+H]+. HPLC: 94.1%
(A) and 94.3% (B).
1-Ethyl-8-(3-methoxyphenyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20c)
General procedure D. Yield: 23%; mp: 169◦C; 1H-NMR (CDCl3)
δ 7.26 (pseudo-t, 3J = 8.20Hz, 1H, H-5, phenyl), 6.57 (dd, 3J
= 8.15Hz, and 4J = 2.55Hz, 1H, H-6, phenyl), 6.51 (dd, 3J =
7.90Hz, and 4J = 1.85Hz, 1H, H-4, phenyl), 6.50 (s, 1H, H-2,
phenyl), 4.77 (d, 4J = 2.20Hz, 2H, N3-CH2), 4.50 (s, 2H, 2 × H-
9), 4.45 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.16 (q, 3J = 7.25Hz, 2H,
N1-CH2), 3.79 (s, 3H, OCH3), 3.71 (t, 3J = 5.35Hz, 2H, 2×H-7),
2.15 (t, 4J = 2.50Hz, 1H, N3-CH2-CH), 1.35 (t, 3J = 7.25Hz, 3H,
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N1-CH2-CH3). ESI-MS: positive mode 380.4 [M+H]+. HPLC:
96.3% (A) and 95.1% (B).
8-(3,4-Dimethoxyphenyl)-1-ethyl-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20d)
General procedure D. Yield: 28%; mp: 125◦C; 1H-NMR (CDCl3)
δ 6.81 (d, 3J = 8.80Hz, 1H, H-6, phenyl), 6.59 (d, 4J = 2.55Hz,
1H, H-2, phenyl), 6.48 (dd, 3J = 8.50Hz, 4J = 2.80Hz, 1H, H-6,
phenyl), 4.77 (d, 4J = 2.20Hz, 2H, N3-CH2), 4.45 (t, 3J = 5.35Hz,
2H, 2 × H-6), 4.41 (s, 2H, 2 × H-9), 4.16 (q, 3J = 7.25Hz, 2H,
N1-CH2), 3.87 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.60 (t, 3J =
5.35Hz, 2H, 2 × H-7), 2.15 (t, 4J = 2.50Hz, 1H, N3-CH2-CH),
1.35 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive mode
410.4 [M+H]+. HPLC: 97.0% (A) and 95.7% (B).
8-Benzyl-1-ethyl-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20e)
General procedure D. Yield: 19%; mp: 148◦C; 1H-NMR (CDCl3)
δ 7.64–7.62 (m, 2H, H-3 and H-5, phenyl), 7.43–7.39 (m, 3H,
H-2, H-4 and H-6, phenyl), 4.86 (s, 2H, N8-CH2), 4.64 (d, 4J =
2.20Hz, 2H, N3-CH2), 4.58 (s, 2H, 2×H-9), 4.45 (t, 3J= 5.35Hz,
2H, 2 × H-6), 3.98 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.83 (t, 3J =
5.35Hz, 2H, 2 × H-7), 2.16 (t, 4J = 2.50Hz, 1H, N3-CH2-CH),
1.21 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive mode:
364.1 [M+H]+. HPLC: 97.0% (A) and 96.7% (B).
1-Ethyl-8-(2-methoxybenzyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20f)
General procedure D. Yield: 26%; mp: 180◦C; 1H-NMR (CDCl3)
δ 7.31–7.29 (m, 1H,H-4, phenyl), 7.28–7.25 (m, 1H,H-6, phenyl),
6.95–6.91 (m, 1H, H-5, phenyl), 6.88 (d, 3J = 8.20Hz, 1H, H-3,
phenyl), 4.75 (d, 4J = 2.50Hz, 2H, N3-CH2), 4.33 (t, 3J = 5.35Hz,
2H, 2 × H-6), 4.12 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.82 (s, 3H,
OCH3), 3.78 (s, 4H, 2×H-9 and N8-CH2), 2.97 (t, 3J = 5.35Hz,
2H, 2 × H-7), 2.13 (t, 4J = 2.50Hz, 1H, N3-CH2-CH), 1.30 (t,
3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive mode 394.3
[M+H]+. HPLC: 97.3% (A) and 98.1% (B).
1-Ethyl-8-(3-methoxybenzyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20g)
General procedure D. Yield: 19%; mp: 157◦C; 1H-NMR (CDCl3)
δ 7.22 (dd, 3J = 6.95Hz, 3J = 7.60Hz, 1H, H-5, phenyl), 6.90
(s, 1H, H-2, phenyl), 6.88 (d, 3J = 6.80Hz, 1H, H-4, phenyl),
6.82 (dd, 3J = 7.25Hz, 4J = 1.55Hz, 1H, H-6, phenyl), 4.75 (d,
4J = 2.55Hz, 2H, N3-CH2), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-
6), 4.12 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.79 (s, 3H, OCH3), 3.74
(s, 2H, N8-CH2), 3.70 (s, 2H, 2 × H-9), 2.93 (t, 3J = 5.35Hz,
2H, 2 × H-7), 2.14 (t, 4J = 2.50Hz, 1H, N3-CH2-CH), 1.30 (t,
3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive mode 394.3
[M+H]+. HPLC: 98.1% (A) and 98.8% (B).
1-Ethyl-8-phenethyl-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1h,3h)-
dione (20h)
General procedure D. Yield: 20%; mp: 144◦C; 1H-NMR (CDCl3)
δ 7.33–7.20 (m, 5H, H-2-H-6, phenyl), 4.74 (d, 4J = 2.55Hz, 2H,
N3-CH2), 4.56 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.26 (s, 2H, 2 ×
H-9), 4.11 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.43 (t, 3J = 5.35Hz,
2H, 2 × H-7), 3.22 (t, 3J = 7.55Hz, 2H, N8-CH2), 3.02 (t, 3J =
7.55Hz, 2H, N8-CH2-CH2), 2.15 (t, 4J = 2.50Hz, 1H, N3-CH2-
CH), 1.35 (t, 3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive
mode: 378.4 [M+H]+. HPLC: 98.2% (A) and 98.8% (B).
1-Ethyl-8-(2-methoxyphenethyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (20i)
General procedure D. Yield: 24%; mp: 167◦C; 1H-NMR (CDCl3)
δ 7.21–7.18 (m, 1H,H-6, phenyl), 7.12–7.10 (m, 1H,H-4, phenyl),
6.89–6.82 (m, 2H, H-3 and H-5, phenyl), 4.76 (d, 4J = 2.20Hz,
2H, N3-CH2), 4.34 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.33 (s, 2H, 2
×H-9), 4.14 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.85 (s, 3H, OCH3),
3.80 (t, 3J = 5.35Hz, 2H, 2 × H-7), 3.32 (t, 3J = 7.55Hz, 2H,
N8-CH2), 2.97 (t, 3J = 7.55Hz, 2H, N8-CH2-CH2), 2.15 (t, 4J =
2.50Hz, 1H, N3-CH2-CH), 1.33 (t, 3J = 7.25Hz, 3H, N1-CH2-
CH3). ESI-MS: positive mode 408.3 [M+H]+. HPLC: 95.6% (A)
and 96.3% (B).
1-Ethyl-8-(3-methoxyphenethyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (20j)
General procedure D. Yield: 21%; mp: 212◦C; 1H-NMR (CDCl3)
δ 7.21–7.18 (m, 1H, H-5, phenyl), 6.80–6.78 (m, H-6, phenyl),
6.76–6.74 (m, 2H, H-2 and H-4, phenyl), 4.75 (d, 4J = 2.50Hz,
2H, N3-CH2), 4.33 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.13 (q, 3J =
7.25Hz, 2H, N1-CH2), 3.82 (s, 2H, 2×H-9), 3.77 (s, 3H, OCH3),
2.96 (t, 3J = 5.35Hz, 2H, 2×H-7), 2.83 (br s, 4H, N8-CH2-CH2),
2.14 (t, 4J = 2.55Hz, 1H, N3-CH2-CH), 1.35 (t, 3J = 7.25Hz, 3H,
N1-CH2-CH3). ESI-MS: positive mode 408.3 [M+H]+. HPLC:
97.0% (A) and 98.5% (B).
1-Ethyl-8-(4-methoxyphenethyl)-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20k)
General procedure D. Yield: 19%; mp: 164◦C; 1H-NMR (CDCl3)
δ 7.11 (dd, 3J = 8.50Hz, 4J = 2.20Hz, 2H, H-2 and H-6, phenyl),
6.84 (dd, 3J = 8.50Hz, 4J = 2.20Hz, 2H, H-3 and H-5, phenyl),
4.75 (d, 4J = 2.50Hz, 2H, N3-CH2), 4.45 (t, 3J = 5.35Hz, 2H,
2 × H-6), 4.22 (s, 2H, 2 × H-9), 4.12 (q, 3J = 7.25Hz, 2H, N1-
CH2), 3.77 (s, 3H, OCH3), 3.39 (t, 3J = 5.35Hz, 2H, 2 × H-7),
3.16 (t, 3J = 7.55Hz, 2H, N8-CH2), 2.96 (t, 3J = 7.55Hz, 2H,
N8-CH2-CH2), 2.15 (t, 4J = 2.50Hz, 1H, N3-CH2-CH), 1.31 (t,
3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive mode 408.3
[M+H]+. HPLC: 95.0% (A) and 94.1% (B).
1-Ethyl-8-(2,3-dimethoxyphenethyl)-3-propargyl-
6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-
dione (20l)
General procedure D. Yield: 25%; mp: 141◦C; 1H-NMR (CDCl3)
δ 6.80–6.71 (m, 3H, H-2, H-5 and H-6, phenyl), 4.77 (d, 4J =
2.50Hz, 2H, N3-CH2), 4.45 (t, 3J = 5.35Hz, 2H, 2 × H-6), 4.39
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(s, 2H, 2 × H-9), 4.11 (q, 3J = 7.25Hz, 2H, N1-CH2), 3.84 (s,
3H, OCH3), 3.85 (s, 3H, OCH3), 3.57 (t, 3J = 5.35Hz, 2H, 2 ×
H-7), 3.32 (t, 3J = 7.55Hz, 2H, N8-CH2), 3.02 (t, 3J = 7.55Hz,
2H, N8-CH2-CH2), 2.16 (t, 4J = 2.20Hz, 1H, N3-CH2-CH), 1.31
(t, 3J = 7.25Hz, 3H, N1-CH2-CH3). ESI-MS: positive mode 438.4
[M+H]+. HPLC: 97.7% (A) and 97.2% (B).
Biological Evaluation
Radioligand Binding Assays at Adenosine Receptors
The following highly (>100-fold) selective radioligands were
employed: A1ARs, [3H]2-chloro-N6cyclopentyladenosine
([3H]CCPA, Klotz et al., 1989, 1 nM, KD human A1: 0.61 nM,
KD: rat A1: 0.2 nM); A2AARs, [3H]3-(3-hydroxypropyl)-7-
methyl-8-(m-methoxystyryl)-1-propargylxanthine ([3H]MSX-2,
Müller et al., 2000, 1 nM, KD human A2A: 7.3 nM, KD: rat
A2A: 8 nM); A2BARs, [3H]8-(4-[4-(4-chlorophenyl)piperazine-
1-sulfonyl]phenyl)-1-propyl-2,3,6,7-tetrahydro-1H-purine-
2,6-Dione ([3H]PSB-603, Borrmann et al., 2009, 0.3 nM, KD
human A2B: 0.41 nM); A3ARs, [3H](R)-8-ethyl-4-methyl-
2-(phenyl)1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one
([3H]PSB-11, Müller et al., 2002, 1 nM, KD human A3: 4.9 nM).
The radioligands were obtained from Quotient Bioresearch
(now Pharmaron): [3H]CCPA (58 Ci/mmol), [3H]MSX-2
(84 Ci/mmol), [3H]PSB-603 (73 Ci/mmol) and [3H]PSB-11
(53 Ci/mmol). The non-radioactive precursors of [3H]MSX-
2, [3H]PSB-603 and [3H]PSB-11 were synthesized in our
laboratory, the precursor for [3H]CCPA was synthesized in the
laboratory of Gloria Cristalli, University of Camerino, Italy.
Membrane preparations and radioligand binding assays at rat
A1 (rat brain cortex) and rat A2A ARs (rat brain striatum) were
performed as previously described (Ozola et al., 2003; Alnouri
et al., 2015). For assays at human A1, A2A, A2B, and A3 ARs,
CHO cell membranes expressing one of the human AR subtypes
were used as previously reported (Klotz et al., 1998; Alnouri
et al., 2015; De Filippo et al., 2016).
Monoamine Oxidase Assay
The determination of MAO-A and MAO-B inhibition was
performed using commercially available recombinant human
MAO-A and MAO-B enzymes expressed in baculovirus-infected
insects sells (Sigma-Aldrich, M7316 and M7441) applying the
commercially available Amplex R© Red monoamine oxidase assay
kit (Invitrogen A12214). The assays were performed as previously
described. The determination of rat MAO-B inhibition was
performed using mitochondrial-enriched fractions from male
Sprague Dawley rat livers. The assays were conducted as
previously described (Stössel et al., 2013).
Molecular Modeling
Molecular Docking Studies at Adenosine Receptors
The recent co-crystal structures of the human A1AR (5N2S.pdb,
Cheng et al., 2017) and the A2AAR (5N2R.pdb, Cheng et al.,
2017) with the antagonist PSB-36 was obtained from the RCSB
(Research Collaboratory for Structural Bioinformatics) Protein
Data Bank (PDB) (Berman et al., 2000). The downloaded
crystal structures were prepared by means of the Molecular
Operation Enviroment (MOE 2016.08), chemical computing
group. Montreal, Quebec, Canada, 2014) protein structure
preparation tool. The hydrogen atoms were assigned according
to Protonate-3D implemented in MOE 2016.08. The crystal
structures of the human A1AR and A2AAR were applied for
flexible ligand docking using AutoDock 4.2 (Morris et al., 2009).
During the docking simulations, the ligands were fully flexible
while the residues of the receptor were treated as rigid. Selected
compounds were docked into the active site of the receptors to
predict the binding modes of the compounds. The atomic partial
charges were added using AutoDockTools (Sanner, 1999; Morris
et al., 2009). Three-dimensional energy scoring grids for a box of
60 × 60 × 60 points with a spacing of 0.375 Å were computed.
The grids were centered based on the co-crystallized ligand, PSB-
36. Fifty independent docking calculations using the varCPSO-ls
algorithm from PSO@Autodock implemented in AutoDock4.2
were performed and terminated after 500,000 evaluation steps
(Namasivayam and Günther, 2007). Parameters of varCPSO-ls
algorithm, the cognitive and social coefficients c1 and c2 were
set at 6.05 with 60 individual particles as swarm size. All the
other parameters of the algorithm were set at their default values.
Possible binding modes of the compounds were explored by
visual inspection of the resulting docking poses.
Molecular Docking Studies at Monoamine Oxidase B
The following programs were used: LigPrep; Maestro;
Schrödinger Suites; Schrödinger, LLC: New York, NY, USA,
2017. The X-ray structure of the complex of human MAO-
B/safinamide with the accession code 2V5Z was downloaded
from the PDB. For the X-ray model, the Protein Preparation
Wizard (Schrödinger Inc.) was used in order to add hydrogen
atoms, to assign partial charges, and to build missing atoms,
side chains and loops. The resulting structures were submitted
to energy optimization by using a specific workflow already
reported in a previous study (Gidaro et al., 2015). The co-
crystallized ligand, safinamide, was used to generate the docking
grid box and to check the prediction of the binding affinity.
Finally, re-docking simulations were carried out in order to
get a protocol validation observing a good capability of the
docking software to reproduce the experimental pose of the
co-crystallized inhibitor. In standard virtual docking studies,
ligands are docked into the binding site of a receptor held as
rigid, and the ligand is free to move. However, the assumption of
a rigid receptor can give misleading results, since in reality many
proteins undergo side-chain or back-bone movements, or both,
upon ligand binding. These changes allow the receptor to adapt
its binding site to the presence of a certain ligand, a process that
is often referred to as the induced fit docking (IFD). This is one
of the main complicating factors in structure-based drug design.
For that reason, docking studies were carried out by using a
specific, previously described IFD workflow (Varela et al., 2012).
An initial Glide SP docking of each ligand was performed by
using a softened potential, a van der Waals radius scaling factor
of 0.50 for receptor/ligand atoms, and a number of 20 poses
per ligand to be energy minimized with the OPLS-2005 force
field. The poses were saved for each ligand and submitted to the
subsequent Prime side chain orientation prediction of residues
with a distance cutoff of 5 Å around each ligand. After the Prime
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SCHEME 1 | Synthesis of 8-substituted 6,7,8,9-tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-diones 11–15. Reagents and conditions: (a) i. glycolic acid (1.2 eq.), 1 h,
100◦C, neat, ii. H2O, NaOH, pH 12–13, 100
◦C, 4 h; (b) 1,2-dibromoethane (6 eq.), dimethylformamide (DMF), DIPEA, 70◦C, 16 h; (c) PBr3 (4 eq.), CH2Cl2, 0
◦C to rt,
1 h; (d) amine (2 eq.), dimethoxyethane, DIPEA, rt, 16 h.
energy minimization of the residues and the ligand for each pose,
a Glide SP re-docking of each protein/ligand complex structure
within 30 kcal/mol above the global minimum was performed.
Finally, each output pose was estimated by the binding energy
(G-score) and visually examined.
RESULTS AND DISCUSSION
Chemistry
The synthetic pathway toward tetrahydropyrazino[2,1-
f ]purinediones 11–15 starting from 5,6-diaminouracil
derivatives 21 is depicted in Scheme 1. Compounds 21
were heated together with glycolic acid to 100◦C, then brought
to pH 12–13 by addition of aqueous NaOH solution, and
subsequently heated for 4 h at 100◦C to accomplish ring
closure reaction yielding 22. 8-Hydroxymethylxanthines
22 were then alkylated in position 7 by reaction with 1,2-
dibromoethane in the presence of diisopropylethylamine
(DIPEA). Finally, the hydroxy function of compounds 23
was reacted with PBr3, and the resulting 7-(2-bromoethyl)-8-
bromomethylpurine-2,4-diones 24 were subsequently treated
with different amines under basic conditions yielding the desired
tetrahydropyrazino[2,1-f ]purinediones 11–15.
Tetrahydropyrazino[2,1-f ]purinediones 16–19 were
synthesized from the corresponding tetrahydropyrazino[2,1-
f ]purinediones 11a, 11b, 12, 13h or 13i by alkylation of the
N3-position with the appropriate alkyl halide using sodium
tert-butoxide or sodium hydride as a base (Scheme 2).
Due to the instability of the propargyl group under
bromination conditions, 1-ethyl-3-propargyl-substituted
tetrahydropyrazino[2,1-f ]purinediones 20 had to be synthesized
in a different manner starting from 1-ethyl-3-propargyl-
5,6-diaminouracil (25) (Scheme 3). Compound 25 was
first reacted with N-boc-glycine in the presence of 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC) to form
the amide bond, then 1-N NaOH/dioxane solution was
added, and the mixture was heated for 10min at 100◦C to
accomplish ring closure yielding 27. The N-boc-protected
8-aminomethylxanthine 27 was subsequently alkylated in
position 7 by treatment with 1,2-dibromoethane/DIPEA.
Finally, the protecting (boc) group was cleaved off under
acidic conditions, and subsequent ring closure under
basic conditions yielded 1-ethyl-3-propargyl-6,7,8,9-
tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-dione (29).
Alkylation of the N8-position with different halides resulted in
the desired tetrahydropyrazino[2,1-f ]purinediones 20.
The structures of all products were confirmed by nuclear
magnetic resonance (1H NMR, and in many cases additional
13C NMR) and mass spectral analyses. Melting points were
determined for all new compounds. The purity of the
tested compounds was confirmed by high-performance liquid
chromatography (HPLC) coupled to electrospray ionizationmass
spectrometry (ESI-MS) using two different methods (for details,
see Experimental Section) and demonstrated to be generally
greater than 95%, except for compounds 20b and 20k (purity >
94%).
Biological Evaluation
The synthesized tetrahydropyrazino[2,1-f ]purinediones 13–
20 were evaluated in radioligand binding assays for their
affinity to A1 ARs of rat brain cortical membrane and to A2A
ARs of rat brain striatal membrane preparations. Selected
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SCHEME 2 | Synthesis of 3-substituted 8-(dichlorobenzyl)-6,7,8,9-tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-diones 16–18, 19a and
8-(2-chloro-5-(trifluoromethyl)benzyl)-1-methyl-3-propargyl-6,7,8,9-tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-dione 19b. Reagents and conditions: (a) MeI (6 eq.),
KOtBu (2 eq.), THF, rt, 4 h; (b) alkyl halide (1.1 eq.), NaH (60% in mineral oil) (1.5 eq.), DMF, 8 h, 60◦C.
compounds were further investigated for their affinity to
human A1 and A2A ARs recombinantly expressed in Chinese
hamster ovary (CHO) cells. All compounds were additionally
investigated for their affinity to human A2B and A3 ARs
recombinantly expressed in CHO cells to determine their
AR subtype selectivity. The following radioligands were
employed for radioligand binding studies: [3H]2-Chloro-N6-
cyclopentyladenosine ([3H]CCPA, A1) (Klotz et al., 1989),
[3H]3-(3-hydroxypropyl)-8-(m-methoxystyryl)-7-methyl-1-
propargylxanthine ([3H]MSX-2, A2A) (Müller et al., 2000),
[3H]8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-
propylxanthine ([3H]PSB-603, A2B) (Borrmann et al., 2009),
and [3H]2-phenyl-8-ethyl-4-methyl-(8R)-4,5,7,8-tetrahydro-
1H-imidazo[2,1-i]purine-5-one ([3H]PSB-11, A3) (Müller et al.,
2002). It is well known that all xanthine derivatives lacking a
ribose moiety, including tricyclic compounds, can only block
ARs, but never act as AR agonists; therefore, additional functional
studies were not required. All compounds were initially tested for
inhibition of human MAO-B at a concentration of 10µM. For
compounds that showed an inhibition of greater than 70% full
concentration-inhibition curves were recorded and IC50 values
were determined. Potent MAO-B inhibitors were additionally
investigated for inhibition of human MAO-A to assess their
selectivity. Results are presented in Tables 1–6, and data of
standard ligands are included for comparison.
Structure-Activity Relationships at Adenosine
Receptors
It should be noted that the N1 of xanthines corresponds
to the N3 of pyrazino[2,1-f ]purinediones and vice versa (see
Table 1). Within the series of the N8-benzyl-substituted 3-
ethyl-1-methyltetrahydropyrazino[2,1-f ]purinediones 14 several
potent A1 AR antagonists and dual A1/A2A AR antagonists
showing Ki values down to the double-digit nanomolar range
were identified (Table 1). As a general trend within this series,
all compounds showed a preference for the A1 vs. the A2A AR at
both the human and the rat ARs. None of the compounds out of
this series showed any significant binding to the human A2B AR.
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SCHEME 3 | Synthesis of 8-substituted 1-ethyl-3-propargyl-6,7,8,9-tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-diones 20. Reagents and conditions: (a) i.
N-boc-glycine (1.3 eq.), EDC (1.3 eq.), MeOH, rt, 1 h; (b) aq. 1N-NaOH/dioxane, 100◦C, 10min; (c) 1,2-dibromoethane (6 eq.), DMF, DIPEA, 70◦C, 16 h; (d) 4N-HCl in
dry dioxane, rt, 0.5 h; (e) 4 eq. DIPEA, dimethoxyethane, rt, 4 h, then R-X (2 eq.), rt, 16 h.
Two derivatives displayed low affinity for the A3 ARs (14c, Ki =
9,390 nM and 14d Ki = 8,760 nM).
The N8-(2-bromobenzyl)-substituted compound 14a was
found to be a potent dual A1/A2A AR antagonist displaying >10-
fold selectivity for the human A1 vs. the human A2A AR (Ki,
A1 AR = 41.7 nM; Ki, A2A AR = 497 nM). Species differences
between the human and rat A1 AR were most prominent in
case of the para-substituted benzyl derivatives. Compounds
14c and 14h were significantly more potent at the rat A1 AR
as compared to the human A1 AR. Further derivatives, 14j-
14q, bearing a disubstituted benzyl moiety at position N8 were
designed, which are lacking a substituent in the para-position.
A 2,3-, 3,4- or 3,5-disubstitution pattern on the benzene ring
was well tolerated by the A1 AR and also improved in most
cases the affinity for the A2A AR. However, compound 14q
bearing two larger CF3-groups in positions 3 and 5 was nearly
inactive.
Compound 14m having a 2-Cl-5-CF3-benzyl moiety at
position N8 of the tetrahydropyrazino[2,1-f ]purinedione core
was found to be a potent A1 AR antagonist at both rat and
human ARs (Ki human A1 = 55.9 nM; Ki rat A1 = 76.2 nM) and
displayed a 16-fold selectivity for the (human) A1 vs. the A2A AR.
None of the designed compounds lacking a substituent
at the N3-position of the tricyclic purinedione core (series
13)—which corresponds to the xanthine N1 position—
displayed any significant affinity for ARs (Table 2). The
presence of a substituent at that position appeared to be
essential for blocking A1 and A2A ARs, e.g., compare 1-
methyltetrahydropyrazino[2,1-f ]-purinedione derivative 13h
with its 1,3-dimethyltetrahydropyrazino[2,1-f ]-purinedione
derivative 10b, or compare 13a and 13b with 14a and 14e,
respectively.
Similar to series 14, all compounds of the N1,N3-diethyl-
substituted tetrahydropyrazino[2,1-f ]purinedione series 15
displayed higher affinity for the A1 than for the A2A AR subtype
(Table 3). Comparison of 15b with 14g as well as 15c with 14i
reveals that elongation of the substituent in the N1-position from
methyl (series 14) to ethyl (series 15) resulted in an increase
in affinity for the A3 AR. The m-bromobenzyl derivative 15d
was found to be a very potent and selective antagonist of the
human and rat A1 AR (Ki, human A1 AR = 13.6 nM; Ki, rat A1
AR = 21.5 nM). Introduction of a second substituent (fluorine
atom) at the benzyl moiety of 15d (compounds 15k and 15l)
resulted in a decrease in both A1 AR affinity and selectivity vs.
the A2A AR.Within the examples having a disubstituted 8-benzyl
moiety, compounds having a trifluoromethyl substituent in
meta-position and second substituent in para- or meta-position
(15i, 15p, 15q) show affinity for the rat A2A AR. However, the A1
AR tolerates am-trifluoromethyl,p-chloro substitution pattern at
the 8-benzyl moiety (15p).
Within the 1-ethyl-3-propargyltetrahydropyrazino[2,1-
f ]purinedione series 20, benzyl derivative 20e was found
to be a balanced dual A1/A2A AR antagonist with good
potency in both species, rat and human (Table 4). Introduction
of a methoxy group in the ortho-position in 20e led to
a similarly potent dual A1/A2A antagonist in humans
(20f, Ki A1 = 210 nM; Ki A2A = 311 nM) but showed
larger species differences in rat. N8-Phenethyl-substituted
tetrahydropyrazinopurinedione 20h was most potent and
selective A2A AR of this series in humans (Ki hA2A = 149 nM).
In case of the rat receptor, the opposite results were observed.
Compound 20h displayed a lower Ki value for the A1 AR
than for A2A AR (Ki A2A = 1,700 nM; Ki A1 = 117 nM). A
methoxy group in the para-position of the phenethyl ring (20k,
20l) led to reduced affinities at both rat adenosine receptor
subtypes.
In the last series of compounds (16–19), the influence of
ethyl and cyclopropyl at the N1-position as well as ethyl and
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TABLE 1 | Adenosine receptor affinities of 3-ethyl-1-methyltetrahydropyrazino[2,1-f ]purinediones 14 and standard antagonists.
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs. [
3H]CCPAa A2A vs. [
3H]MSX-2a A2B vs. [
3H]PSB-603b A3 vs. [
3H]PSB-11b
Istradefylline (1)c 841 (h) 12 (h) >10,000 (h) 4,470 (h)
230 (r) 4.46 (r)
Caffeine (2)c 44,900 (h) 23,400 (h) 33,800 (h) 13,300 (h)
41,000 (r) 32,500 (r) 30,000 (r) >10,000 (r)
CSC (3)c >10,000 (14%)d
(h)
38.0 ± 11.0 (h) 8,200 (h) >10,000 (h)
28,000 (r) 54 (r)
3-ETHYL-1-METHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 14
14a 41.7 ± 8.3 (h) 497 ± 62 (h) >1,000 (h) (18%)d >10,000 (h) (36%)d
123 ± 34 (r) 408 ± 90 (r)
14b 70.7 ± 12.3 (h) >1,000 (h) (9%)d >10,000 (h) (39%)d
28.8 ± 1.5 (r) 1,140 ± 160 (r)
14c 1,350 ± 340 (h) >1,000 (h) (1%)d 9,390 ± 1,830 (h)a
156 ± 21 (r) >1,000 (r) (35%)d
14d 244 ± 74 (h) >1,000 (h) (2%)d 8,760 ± 930 (h)a
114 ± 15 (r) >1,000 (r) (20%)d
14e 156 ± 49 (h) 1,780 ± 770 (h) >100 (h) (2%)d >10,000 (h) (38%)d
49.1 ± 6.2 (r) 708 ± 25 (r)
14f >100 (h) (1%)d 18,600 ± 2,800 (h)a
>1,500 (r) (9%)d >1,000 (r) (7%)d
14g 85.3 ± 5.5 (h) >100 (h) (15%)d >10,000 (h) (24%)d
59.4 ± 7.7 (r) >1,000 (r) (18%)d
14h 5,120 ± 150 (h) >1,000 (h) (9%)d >10,000 (h) (37%)d
164 ± 28 (r) >1,000 (r) (7%)d
14i 121 ± 45 (h) >1,000 (h) (8%)d >10,000 (h) (36%)d
53.0 ± 5.8 (r) >1,000 (r) (33%)d
14j 391 ± 77 (h) 906 ± 73 (h) >1,000 (h) (2%)d >10,000 (h) (42%)d
36.9 ± 6.1 (r) 617 ± 114 (r)
14k 197 ± 5 (h) >1,000 (h) (8%)d >10,000 (h) (17%)d
142 ± 32 (r) 1,100 ± 380 (r)
(Continued)
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TABLE 1 | Continued
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs.
[3H]CCPAa
A2A vs.
[3H]MSX-2a
A2B vs.
[3H]PSB-603b
A3 vs.
[3H]PSB-11b
14l 495 ± 80 (h) 2,020 ± 480 (h) >1,000 (h) (8%)d >10,000 (h) (29%)d
236 ± 57 (r) 667 ± 68 (r)
14m 55.9 ± 8.3 (h) 881 ± 96 (h) >1,000 (h) (3%)d >10,000 (h) (35%)d
76.2 ± 9.0 (r) 592 ± 28 (r)
14n 298 ± 52 (h) >1,000 (h) (1%)d 15,600 ± 4,000 (h)a
36.2 ± 9.9 (r) 981 ± 116 (r)
14o 116 ± 27 (h) 1,700 ± 150 (h) >1,000 (h) (11%)d >10,000 (h) (39%)d
36.0 ± 18.4 (r) 880 ± 174 (r)
14p 330 ± 67 (h) 503 ± 121 (h) >1,000 (h) (5%)d >10,000 (h) (39%)d
111 ± 25 (r) 801 ± 99 (r)
14q >1,000 (h) (2%)d >10,000 (h) (32%)d
>1,500 (r) (31%)d >1,000 (r) (39%)d
an = 3.
bn = 2.
cdata taken from Müller and Jacobson (2011); Brunschweiger et al. (2014).
d% inhibition of radioligand binding at indicated concentration.
propargyl at the N3-position was probed (Table 5). These were
combined with a 3,4-dichlorobenzyl substituent at N8 as in lead
structure 10b (1,3-dimethyl-substituted analog, see Figure 3).
Compound 16a was found to be a potent dual A1/A2A AR
antagonists with ancillaryMAO-B inhibitory activity, similarly to
10b. Switching from a 3,4-dichloro substitution pattern (16a) of
the benzyl moiety to 3,5-dichloro substitution (in 16b) resulted
in an improvement in affinity for both human and rat A1
AR. Compared to 16a, a cyclopropyl moiety at the N1-position
(compound 17) was less tolerated. A propargyl substituent at
N3 combined with a 3,4-dichlorobenzyl at position N8 (19a)
somewhat improved the affinity for the human A3 AR. Changing
the substitution pattern on the benzyl ring from 3,4-dichloro to
2-chloro-5-trifluoromethyl (in 19b) eliminated the affinity for the
A3 AR and increased the affinity for the A1/A2A ARs.
Docking Studies at A1 and A2A Adenosine Receptors
As shown in Figures 5A,B, the purinedione core structure
of the dual A1/A2A AR antagonist 16a forms one of the
key π-π stacking interactions with Phe171 and utilizes the
hydrophobic surface provided by Leu250 in the human A1
AR. The carbonyl group at position C4 which corresponds
to the C6-carbonyl of xanthine forms another key hydrogen
bond interaction with Asn254. The methyl substituent at N1
(corresponding to N3 of xanthine) of purinedione derivative 16a
binds within the hydrophobic sub-pocket formed by the residues
Leu88, Met180 and Leu250. Similarly, the ethyl substituent
at N3 binds in another sub-pocket formed by Ala66, Ile69,
Val87, Ile274, and His278. The 3,4-dichlorobenzyl substitution
at N8 was found to occupy the pocket formed by the residues
Tyr12, Ile69, Asn70, Glu170, Glu172, Ser267, and Tyr271. The
tetrahydropyrazine ring which is annelated to the xanthine
core, and the methylene group in the benzyl moiety direct the
aromatic substituent into a specific binding pocket. A possible
electrostatic interaction between the chloro substituent at the
3-position of the benzyl moiety and Glu170 may be beneficial
for interaction with the human A1AR. This was supported by
the observed high affinity of compound 16b with 3,5-dichloro
substitution, a modification which possibly increases the chance
to form interactions with Glu170. In comparison to classical 8-
substituted xanthine derivatives such as PSB-36 found in recently
published X-ray structures (Cheng et al., 2017), compound 16a
and related compounds featuring a tricyclic core structure are
somewhat less potent possibly due to the loss of the free N7-H
in xanthines, which forms interactions with Asn254 or water-
mediated interactions with Glu172.
As shown in Figures 5C,D, compound 16a follows a similar
interaction pattern in the human A2A AR for the purinedione
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TABLE 2 | Adenosine receptor affinities of 1-methyltetrahydropyrazino[2,1-f ]purinediones 13.
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs. [
3H]CCPAa A2A vs. [
3H]MSX-2a A2B vs. [
3H]PSB-603b A3 vs. [
3H]PSB-11b
13a >1,000 (h) (1%)c 14,700 ± 4,700 (h)a
>1,500 (r) (17%)c >1,000 (r) (-23%)c
13b >1,000 (h) (2%)c >10,000 (h) (35%)c
>1,500 (r) (−1%)c >1,000 (r) (5%)c
13c >1,000 (h) (18%)c >10,000 (h) (49%)c
>1,500 (r) (3%)c >1,000 (r) (1%)c
13d >1,000 (h) (1%)c ca. 10,000 (h) (45%)c
>1,500 (r) (1%)c >1,000 (r) (15%)c
13e >300 (h) (8%)c >10,000 (h) (39%)c
>1,500 (r) (9%)c >1,000 (r) (4%)c
13f >1,000 (h) (1%)c 17,200 ± 4,500 (h)a
>1,500 (r) (5%)c >1,000 (r) (19%)c
13g >1,000 (h) (1%)c >10,000 (h) (41%)c
>1,500 (r) (3%)c >1,000 (r) (10%)c
13h >1,000 (h) (3%)c >1,000 (h) (14%)c
>1,500 (r) (36%)c >1,000 (r) (−9%)c
an = 3.
bn = 2.
c% inhibition of radioligand binding at indicated concentration.
core forming key hydrophobic and hydrogen bond interactions
with Phe168 and Asn253, respectively, as observed for the
human A1AR. The orthosteric binding pocket where the tricyclic
purinedione binds is largely identical among all subtypes of
human ARs. The 3,4-dichlorobenzyl substitution at N8 also
occupies a similar binding pocket in the human A2A AR as
found in docking studies of the human A1 AR. However, the
lack of electrostatic interactions with the chloro substituents
at the benzyl moiety may reduce the binding affinity at the
human A2A AR in comparison to the human A1 AR, since
the glutamic acid (Glu170 in the human A1 AR) is replaced
with a non-polar leucine (Leu167) in the human A2A AR.
The selectivity of compound 16a vs. the two other human AR
subtypes, A2B and A3, may be explained by different residues,
lysine and glutamate, respectively, which are present in the
binding pocket in comparison to Ser267 (human A1 AR) or
Leu267 (human A2A AR). The different amino acid residues
would require different substitution patterns on the tricyclic ring
system in order to result in binding affinity for the human A2B
and A3 ARs.
We additionally docked the A1-selective compound 15d
(Figure 6A), which contains a m-bromobenzyl residue. Its
selectivity for the A1 vs. the A2A AR can be explained by
strong electrostatic interactions between bromine and Glu170.
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TABLE 3 | Adenosine receptor affinity of 1,3-diethyltetrahydropyrazino[2,1-f ]purinediones 15.
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs. [
3H]CCPAa A2A vs.
[3H]MSX-2a
A2B vs. [
3H]PSB-603b A3 vs. [
3H]PSB-11b
15a 156 ± 5 (h) >1,000 (h) (12%)c 7,820 ± 1,240 (h)a
32.0 ± 0.9 (r) 2,000 ± 430 (r)
15b 207 ± 11 (h) >1,000 (h) (9%)c 7,020 ± 870 (h)a
47.2 ± 19.9 (r) 1,580 ± 80 (r)
15c 128 ± 17 (h) 2,380 ± 70 (h) >1,000 (h) (12%)c 5,410 ± 850 (h)a
85.9 ± 28.6 (r) >1,000 (r) (22%)c
15d
(PSB-18339)
13.6 ± 2.1 (h) 1,050 ± 300 (h) 496 ± 135 (h)a 7,220 ± 1,170 (h)a
21.5 ± 8.3 (r) 1,040 ± 90 (r)
15e 4,420 ± 1,170 (h) >1,000 (h) (39%)c >1,000 (h) (12%)c
54.0 ± 9.1 (r) 1,140 ± 290 (r)
15f 129 ± 9 (h) >1,000 (h) (2%)c 4,060 ± 930 (h)a
51.4 ± 14.7 (r) >1,000 (r) (32%)c
15g 84.8 ± 2.4 (h) 277 ± 59 (h) >1,000 (h) (27%)c >10,000 (h) (36%)c
30.0 ± 5.7 (r) 1,030 ± 130 (r)
15h 189 ± 29 (h) 663 ± 54 (h) >1,000 (h) (30%)c >10,000 (h) (29%)c
172 ± 28 (r) 895 ± 210 (r)
15i >1,000 (h) (33%)c >10,000 (h) (36%)c
>1,500 (r) (19%)c >1,000 (r) (30%)c
15j 39.4 ± 7.4 (h) 781 ± 68 (h) >1,000 (h) (27%)c >10,000 (h) (25%)c
124 ± 21 (r) 600 ± 54 (r)
15k 362 ± 98 (h) 756 ± 271 (h) >1,000 (h) (34%)c 7,190 ± 2,200 (h)a
270 ± 60 (r) >1,000 (r) (30%)c
(Continued)
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TABLE 3 | Continued
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs. [
3H]CCPAa A2A vs.
[3H]MSX-2a
A2B vs. [
3H]PSB-603b A3 vs. [
3H]PSB-11b
15l 75.4 ± 16.1 (h) 598 ± 92 (h) >1,000 (h) (24%)c 13,300 ± 4,300 (h)a
33.5 ± 5.6 (r) 756 ± 46 (r)
15m 207 ± 48 (h) 631 ± 122 (h) >1,000 (h) (23%)c 4,720 ± 720 (h)a
89.6 ± 21.4 (r) 2,200 ± 180 (r)
15n 22.6 ± 2.7 (h) 613 ± 34 (h) >1,000 (h) (23%)c >10,000 (h) (38%)c
19.6 ± 3.0 (r) 871 ± 50 (r)
15o >1,000 (h) (16%)c 1,690 ± 320 (h)c
>1,500 (r) (41%)c >1,000 (r) (19%)c
15p 129 ± 22 (h) >1,000 (h) (32%)c 7,180 ± 860 (h)c
588 ± 28 (r) >1,000 (r) (40%)c
15q >1,000 (h) (7%)c >10,000 (h) (40%)c
>1,500 (r) (6%)c >1,000 (r) (13%)c
15r 1,190 ± 27 (h) 4,110 ± 890 (h) >1,000 (h) (23%)c >10,000 (h) (14%)c
>1,500 (r) (25%)c >1,000 (r) (36%)c
an = 3.
bn = 2.
c% inhibition of radioligand binding at indicated concentration.
This may be the reason for the increased affinity of the
bromo-substituted benzyl derivative in comparison to the fluoro-
(15b) or the chloro- (15c) substituted analogs. The A2A-
selectivity of compound 20h (Figure 6B), a phenethyl derivative,
is likely due to strong hydrophobic interaction with Met270,
which controls the positioning of the compound toward the
binding pocket. The obtained orientation of 20h may be further
stabilized by hydrophobic interactions with the residues Leu167
and Leu267. The proposed hypothesis that the hydrophobic
residue Met270 likely plays a role is supported by the results at
the rat A1 AR, in which that methionine is replaced by isoleucine
(Ile270) showing better affinity in comparison to threonine
(Thr270) present in the human A1 AR (see Sequence Alignment
in Figure S1, Supplementary Material).
Species Differences at Adenosine Receptors
The majority of compounds was investigated at both, rat as
well as human A1 and A2A ARs. This was done because
previous studies had revealed major species differences for
some classes of AR antagonists between human and rodent
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TABLE 4 | Adenosine receptor affinity of 1-ethyl-3-propargyltetrahydropyrazino[2,1-f ]purinediones 20.
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs. [
3H]CCPAa [3H]MSX-2a A2B vs.[
3H]PSB-603b A3 vs. [
3H]PSB-11b
20a >1,000 (h) (8%)c 4,270 ± 890 (h)a
1,140 ± 260 (r) 1,380 ± 260 (r)
20b 1,530 ± 180 (h) 378 ± 49 (h) >1,000 (h) (15%)c 2,390 ± 340 (h)a
410 ± 60 (r) 128 ± 20 (r)
20c 946 ± 166 (h) 289 ± 85 (h) >1,000 (h) (38%)c 7,160 ± 950 (h)a
328 ± 70 (r) 250 ± 80 (r)
20d 1,670 ± 320 (r) 1,580 ± 340 (r) >1,000 (h) (8%)c 3,640 ± 720 (h)a
20e (PSB-1869) 180 ± 28 (h) 282 ± 38 (h) >1,000 (h) (2%)c >10,000 (h) (35%)c
118 ± 28 (r) 245 ± 39 (r)
20f 210 ± 90 (h) 311 ± 106 (h) >1,000 (h) (18%)c 7,640 ± 700 (h)a
32.7 ± 5.8 (r) 1,200 ± 140 (r)
20g 124 ± 90 (h) 542 ± 169 (h) >1,000 (h) (22%)c >10,000 (h) (40%)c
118 ± 22 (r) 769 ± 77 (r)
20h 2,440 ± 400 (h) 149 ± 28 (h) >1,000 (h) (16%)c >10,000 (h) (36%)c
117 ± 2 (r) 1,700 ± 160 (r)
20i 1,260 ± 250 (h) 3,230 ± 730 (h) >1,000 (h) (24%)c 5,830 ± 370 (h)a
701 ± 204 (r) 883 ± 265 (r)
20j 1,020 ± 350 (h) 25,500 ± 5,400 (h) >1,000 (h) (11%)c >10,000 (h) (13%)c
669 ± 35 (r) 798 ± 134 (r)
20k 1,600 ± 610 (r) 2,700 ± 300 (r) >1,000 (h) (10%)c >10,000 (h) (22%)c
20l 3,800 ± 330 (r) 7,400 ± 220 (r) >1,000 (h) (9%)c >10,000 (h) (12%)c
an = 3.
bn = 2.
c% inhibition of radioligand binding at indicated concentration.
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TABLE 5 | Adenosine receptor affinities of 1-ethyl-3-methyltetrahydropyrazino[2,1-f ]purinediones 16, 1-cyclopropyl-3-methyltetrahydropyrazino[2,1-f ]purinedione 17,
1-methyl-3-propyltetrahydropyra-zino[2,1-f ]purinedione 18 and 1-methyl-3-propargyltetrahydropyrazino[2,1-f ]purinediones 19.
Ki ± SEM (nM) human (h); rat (r)
Compd R A1 vs. [
3H]CCPAa A2A vs.[
3H]MSX-2a A2B vs. [
3H]PSB-603b A3 vs. [
3H]PSB-11b
1-ETHYL-3-METHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 16
16a (PSB-18405) 396 ± 154 (h) 1,620 ± 280 (h) >1,000 (h) (5%)c >10,000 (h) (19%)c
236 ± 23 (r) 1,100 ± 390 (r)
16b 143 ± 16 (h) 2,230 ± 640 (h) >1,000 (h) (5%)c >10,000 (h) (23%)c
49.3 ± 8.0 (r) 1,490 ± 270 (r)
1-CYCLOPROPYL-3-METHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONE 17
17 1,130 ± 180 (h) >100 (h) (2%)c >10,000 (h) (26%)c
584 ± 8 (r) 3,940 ± 390 (r)
1-METHYL-3-PROPYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONE 18
18 475 ± 47 (h) 2,110 ± 370 (h) >1,000 (r) (33%)c 12,700 ± 2,500 (h)a
152 ± 12 (r) 675 ± 104 (r)
1-METHYL-3-PROPARGYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 19
19a 967 ± 211 (h) 1,580 ± 550 (h) >1,000 (h) (23%)c 5,630 ± 210 (h)a
292 ± 21 (r) 642 ± 194 (r)
19b 110 ± 4 (h) 712 ± 129 (h) >1,000 (h) (3%)c >10,000 (h) (25%)c
153 ± 10 (r) 414 ± 49 (r)
an = 3.
bn = 2
c% inhibition of radioligand binding at indicated concentration.
receptors (Maemoto et al., 1997; Burbiel et al., 2016; Szymanska
et al., 2016). Rats or mice are typically used for preclinical
studies. Therefore, it is important to determine the affinity
of tool compounds and preclinical drug candidates in rodent
species. The correlation of pKi values obtained at rat vs.
human A1 and A2A ARs is depicted in Figure 7. Many of
the compounds were somewhat more potent at rat than at
human receptors, although for some compounds the opposite
was true. The correlation was in general quite good (less than
3–5-fold difference in Ki values), although some outliers were
observed (see Figure 7) confirming subtle differences in the
binding sites.
Structure-Activity Relationships at Monoamine
Oxidases
The inhibitory activities of the tetrahydropyrazino[2,1-
f ]purinediones 13–20 at human MAO-A and MAO-B are
listed in Table 6. All compounds, tested at a concentration
of 10µM, were found to be inactive at MAO-A. In case of
MAO-B, compound 13g bearing a 3,4-dichlorophenethyl moiety
at the N8-position was the only example within the series of
1-methyltetrahydropyrazino[2,1-f ]purinediones 13 displaying
an IC50 value in the submicromolar range. Alteration of the
substitution pattern on the phenyl ring from 3,4-dichloro to
2,4-dichloro resulted in a 3-fold reduction in MAO-B inhibitory
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TABLE 6 | MAO-A and MAO-B inhibition of tetrahydropyrazino[2,1-f ]purinediones
13–20 and standard inhibitors.
IC50 ± SEM (nM)
a
Compd. Human MAO-A Human MAO-B
STANDARD COMPOUNDS
Selegiline ndb 6.13 ± 0.85
Safinamide nd 7.67 ± 1.81
Lazabemide nd 17.6 ± 4.2
Istradefylline (1) >10,000 (18%)c >10,000 (20%)c
Caffeine (2) >500,000 (33%)c >500,000 (16%)c
CSC (3) >10,000 (23%)c 18.1 ± 3.3
1-METHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 13
13a >10,000 (13%)c 4,530 ± 150
13b nd >10,000 (14%)c
13c nd ca. 10,000 (54%)c
13e nd ca. 10,000 (47%)c
13f >10,000 (13%)c 2,880 ± 330
13g >10,000 (12%)c 864 ± 64
13h >10,000 (12%)c 1,090 ± 70
3-ETHYL-1-METHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 14
14a nd >10,000 (37%)c
14b nd >10,000 (34%)c
14c >10,000 (2%)c 1,630 ± 120
14d >10,000 (5%)c ≥10,000 (49%)c
14e >10,000 (12%)c <10,000 (64%)c
14f nd >10,000 (32%)c
14g nd ≥10,000 (48%)c
14h nd >10,000 (24%)c
14i >10,000 (20%)c ≤10,000 (54%)c
14j >10,000 (23%)c 3,980 ± 750
14k nd >10,000 (43%)c
14l >10,000 (8%)c <10,000 (65%)c
14m >10,000 (9%)c 1,430 ± 60
14n >10,000 (19%)c 3,740 ± 350
14o >10,000 (15%)c 3,070 ± 180
14p nd >10,000 (23%)c
14q >10,000 (8%)c <10,000 (56%)c
1,3-DIETHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 15
15a nd >10,000 (22%)c
15b nd ≥10,000 (49%)c
15c nd ≥10,000 (47%)c
15d (PSB-18339) nd ≥10,000 (49%)c
15e >10,000 (25%)c 6,510 ± 270
15f nd >10,000 (41%)c
15g nd >10,000 (10%)c
15h nd >10,000 (32%)c
15i >10,000 (8%)c 3,070 ± 200
15j >10,000 (7%)c <10,000 (58%)c
15k >10,000 (−10%)c <10,000 (63%)c
15l >10,000 (8%)c 1,310 ± 160
15m >10,000 (1%)c <10,000 (66%)c
15n >10,000 (−4%)c ≤10,000 (54%)c
(Continued)
TABLE 6 | Continued
IC50 ± SEM (nM)
a
Compd. Human MAO-A Human MAO-B
15o nd >10,000 (5%)c
15p >10,000 (6%)b <10,000 (67%)c
15q nd >10,000 (27%)c
15r >10,000 (7%)c 524 ± 26
1-ETHYL-3-METHYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONES 16
16a (PSB-18405) >10,000 (6%)c 106 ± 10
16b >10,000 (8%)c 136 ± 5
1-CYCLOPROPYL-3-METHYLTETRAHYDROPYRAZINO[2,1-f]
PURINEDIONE 17
17 >10,000 (7%)c 3,690 ± 250
1-METHYL-3-PROPYLTETRAHYDROPYRAZINO[2,1-f]PURINEDIONE 18
18 >10,000 (9%)c 2,910 ± 110
1-METHYL-3-PROPARGYLTETRAHYDROPYRAZINO[2,1-f]
PURINEDIONES 19
19a >10,000 (12%)c 679 ± 17
19b >10,000 (5%)c <10,000 (59%)c
1-ETHYL-3-PROPARGYLTETRAHYDROPYRAZINO[2,1-f]
PURINEDIONES 20
20a nd >10,000 (29%)c
20b nd >10,000 (35%)c
20c >10,000 (6%)c ≤10,000 (51%)c
20d nd >10,000 (13%)c
20e (PSB-1869) nd >10,000 (20%)c
20f nd >10,000 (27%)c
20g nd >10,000 (41%)c
20h nd >10,000 (27%)c
20i nd >10,000 (26%)c
20j nd >10,000 (30%)c
20k nd >10,000 (25%)c
20l nd >10,000 (3%)c
an = 3.
bnd, not determined.
c% inhibition at indicated concentration.
potency. The length of the linker between N8 and the di-
chlorophenyl ring was not that important for the inhibitory
activity. Shortening of the linker by one methylene group
resulted only in a negligible decrease of inhibitory activity
(compare 13h vs. 13g).
Moderately to weakly active MAO-B inhibitors
could also be identified in the series of 3-ethyl-1-
methyltetrahydropyrazino[2,1-f ]purinediones 14. In the
group of compounds having a mono-substituted (halogen
or trifluoromethyl) benzyl ring at the N8-position (14a-i),
4-bromo-derivative 14c displayed the highest MAO-B inhibitory
potency (IC50 = 1,630 nM). Compounds 14e and 14i having a
CF3 or Cl at position 3 of the aromatic ring, respectively, also
showed an inhibition of greater than 50% at a test concentration
of 10µM. In case of the compounds bearing two substituents
on the phenyl ring, a 2,5-disubstitution pattern was shown to be
favorable for MAO-B inhibition (compounds 14j, 14m, 14o).
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FIGURE 5 | Putative binding pose of 16a. (A) Docked pose of 16a (yellow) in the binding pocket of the human A1 AR; (B) shows important amino acids in the binding
pocket that are believed to interact with 16a. (C) Docked pose of 16a (yellow) in the binding pocket of the human A2A AR; (D) shows important amino acids in the
binding pocket that likely interact with 16a. The human A1 AR (pale green) and the human A2A AR (gray) are displayed in the cartoon representation, the important
amino acids as stick model. Oxygen atoms are colored in red, nitrogen atoms in blue, and sulfur in yellow. The interactions are indicated by red dotted lines, and
amino acids found to be responsible for the key interactions are encircled in black.
FIGURE 6 | Putative binding pose of 15d (A1-selective) and 20h (A2A-selective). (A) Docked pose of 15d (marine blue) with the important amino acids in the binding
pocket of the human A1 AR. (B) Docked pose of 20h (orange) with the important amino acids in the binding pocket of the human A2A AR. The interactions are
indicated by red dotted lines and the important amino acids responsible for selectivity are encircled in black.
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FIGURE 7 | Correlation of affinities at human vs. rat A1 and A2A ARs.
Within the series of 1,3-diethyl-substituted
tetrahydropyrazino[2,1-f ]purinediones 15, compounds having
a di-substituted phenyl ring (15i-q) showed a higher MAO-
B inhibitory potency as compared to the mono-substituted
derivatives of this series (15a-h). In general, a 3,5- and a
3,4-disubstitution pattern of the phenyl ring was beneficial
for MAO-B inhibition. The most potent MAO-B inhibitor
of this series was derivative 15r (IC50 = 524 nM) bearing an
3,4,5-trifluorobenzyl moiety at the N8-position. This is in
good agreement with results observed within the reported
1,3-dimethyltetrahydropyrazino[2,1-f ]purine-2,4-dione series
(Brunschweiger et al., 2014).
Comparison of all tetrahydropyrazino[2,1-f ]purinediones
bearing a 3,4-dichlorobenzyl moiety at the N8-position
(compounds 13h, 16a, 17, 18, and 19a) revealed that the
N1-ethyl and N3-methyl substitution pattern was the best
for MAO-B inhibition. Dual A1/A2A AR antagonist 16a
was the most potent MAO-B inhibitor of the present series
showing an IC50 value in the nanomolar range (IC50 =
106 nM). Dual A1/A2A AR antagonist 16b having a 3,5-dichloro
substitution pattern on the benzene ring inhibited MAO-B
(IC50 =136 nM) with almost equal potency as its 3,4-dichloro
isomer 16a.
The only compound of the 3-ethyl-1-
methyltetrahydropyrazino[2,1-f ]purinediones series 20
displaying inhibition of more than 50% at a high test
concentration of 10µM was 20c bearing a 3-methoxyphenyl
moiety at the N8-position, whereas all other derivatives of this
series were inactive.
Docking Studies at Monoamine Oxidase B
In Figure 8, the main interactions between MAO-B and
inhibitors 16a (A) and 16b (B), the two active compounds, are
depicted. Stacking interactions appear to stabilize the tricyclic
inhibitors 16a and 16b within the MAO-B binding site. In case
of 20l, which was randomly selected from the group of inactive
compounds, this kind of contacts are not detected, which may be
the reason for its different biological profile. It is worth noting
that Tyr326 in the active site plays an essential role in binding: it
is likely involved in interactions with the two active inhibitors 16a
and 16b, as with the standard inhibitor safinamide (Binda et al.,
2007). Moreover, as we recently observed in case of linear ligands
(Carradori et al., 2016; Meleddu et al., 2017), opposite head-tail
orientations can easily occur according to docking results due to
comparable energy levels. The presence of Cl at position 5 on
the benzyl moiety of 16b induces a modest steric hindrance with
Tyr188, sufficient to force its inverted orientation in the best pose
with respect to 16a.
A comparative analysis performed by the induced-fit docking
G-score estimation revealed that compound 16b can establish
a better molecular recognition within the MAO-B isoform with
respect to MAO-A. The G-score gap is in the order of about 6.7
kcal/mol and likely due to the different binding pocket volumes
between those isoforms (Alcaro et al., 2010). The π-π interaction
of 16b with Tyr326 in MAO-B (Figure 8B) cannot be established
in the isoform A, where this residue is replaced with and Ile
residue.
Water Solubility
1,3,8-Substituted tetrahydropyrazino[2,1-f ]purine-2,4(1H,3H)-
diones have previously been shown to possess excellent water-
solubility at pH 1 due to protonation of the nitrogen
atom N8 (Brunschweiger et al., 2014). This is expected
to facilitate dissolution in the stomach. Depending on the
substitution pattern they may also be well soluble at higher pH
values (Brunschweiger et al., 2014). In the present study we
measured thermodynamic solubility of only very few compounds
exemplarily (14a-e, 14g, 15f,g) and confirmed their high
solubility at pH 1 (see Table S1 in Supplementary Material). Most
of these compounds were still soluble at pH 7.4. The best
soluble derivative was the 3-ethyl-1-methyl-8-m-fluorobenzyl
derivative 14g with solubilities of >1.5 g/L (4.2mM) at pH 1,
50 mg/L (0.14mM) at pH 4, and 40 mg/L (0.084mM) at pH
7.4.
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FIGURE 8 | Molecular interactions (A) between inhibitor 16a and MAO-B, and
(B) between 16b and MAO-B. The protein is shown as gray cartoon while the
ligands are shown as green carbon sticks; H-bonds and π-π interactions are
depicted as dashed black and cyan lines respectively. Amino acid residues
involved in the interactions are shown as gray sticks. The covalently bound
cofactor flavine adenine dinucleotide (FAD) is depicted on the left hand side as
green sticks. Nitrogen atoms are in blue, oxygen atoms in red, hydrogen
atoms in white, phosphorus atoms in purple.
CONCLUSIONS
A large library of novel 1,3,8-substituted tetrahydropyrazino[2,1-
f ]purinediones was synthesized. For the first time we
systematically and extensively studied the exchange of methyl
groups in the 1- and 3-position of the theophylline-/caffeine-
derived tricyclic scaffold for a variety of alkyl residues including
cyclic and unsaturated ones. Series of compounds with different
1- and 3-substituent were also obtained. The compounds were
tested for antagonistic potency at all four ARs as well as for
inhibitory potency at both MAO enzymes with the goal to
improve potency at A1 and A2A ARs and MAO-B, which
are (potential) targets for the treatment of neurodegenerative
diseases, in particular for PD. The A1 AR affinity was dramatically
improved by 3-ethyl-1-methyl (e.g., 14a), 1,3-diethyl (15d) and
1-ethyl-3-propargyl (20e) substitution. Good A2A affinity was
obtained for 3-ethyl-1-propargyl derivatives 20, e.g., 20h and
20e. Compounds with a balanced A1/A2A inhibitory potency
were also obtained in this group (e.g., 20e). Significantly
increased MAO-B inhibitory activity while keeping selectivity
vs. the isoenzyme MAO-A, which is important to avoid side-
effects, was obtained by 1-ethyl-3-methyl substitution of the
pyrazinopurinedione structure (16a, 16b). Molecular docking
studies based on recently published X-ray structures of A1 and
A2A ARs, and of MAO-B supported the results obtained by
SAR analysis. Besides modulating affinities, replacement of the
methyl groups in the 1- and 3-position of pyrazinopurinediones
may also be useful for fine-tuning metabolic stability of the
compounds since the methyl groups of caffeine and theophylline
are known to be subject to oxidative demethylation (Fredholm
et al., 1999). The present study provides new insights into
the SARs of tricyclic xanthine derivatives, which are suitable
scaffolds for multi-target drug development. As a next important
step, such multi-target drugs will have to be tested in in vivo
models in comparison to drugs selective for a single target to
prove their potential superiority.
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